



# BIO CHINA

## International Convention

March 13-15, 2025  
Suzhou International Expo Center



## Honorary Chairman



**Kaixian Chen**  
Academician of  
*Chinese Academy  
of sciences*



**Zixin Deng**  
Academician of  
*Chinese Academy of  
Sciences*

## General Chairman



**Piaoyang Sun**  
*Hengrui Pharma*  
Chairman

## Expert Committee



**Zhihong chen**  
*Curon  
Biopharmaceutical  
(Shanghai)Ltd*  
CEO



**Dong Chen**  
*Academician of Chinese  
Academy of Sciences*  
Dean of Medical school of  
*Westlake University*



**Aimin Hui**  
Chair & CEO of  
*EnCureGen Pharma*  
Professor of State Key  
*Laboratory of  
Respiratory Diseases*



**Linong Ji**  
*Peking University  
People's Hospital*  
Director of the  
*Department of  
Endocrinology and Metabolism*



**Ning Li**  
*TopAlliance  
Biosciences*  
Chairman



**Zonghai Li**  
*CARsgen*  
Chairman & CEO



**Yong Jun Liu**  
*CSPC PHARMA.*  
Executive president  
President Global R&D



**Shen Lin**  
*Peking University Cancer  
Hospital* Director of the  
Department of  
*Gastrointestinal Oncology*



**Su Bing**  
Wang Kuan-Cheng  
Chair Professor of  
*Shangha Jiliao Tong  
University*  
Director of *Shanghai  
Institute of Immunology*



**Weikang Tao**  
*Oilu Pharmaceutical Group  
Corp* VP and President of  
Global R&D of Innovative  
Medicines



**Huji Xu**  
*Shanghai  
Changzheng  
Hospital* Professor



**Lianshan Zhang**  
*Jiangsu Hengrui  
Pharmaceuticals*  
Board Director & Vice  
President



**Caicun Zhou**  
*Shanghai East Hospital*  
Director











**John Zhu**  
*Duality Biologics*  
Founder & CEO



**Jin Li**  
Dean,  
*Shanghai Gaobo  
Oncology Hospital,  
China Pharmaceutical  
University*

**Industrial Forum Planner** (Sort by Confirmation Time)

- |   |  |   |  |   |   |  |   |
|---|--|---|--|---|---|--|---|
| <br>Michael Yin,<br>Chairman, <i>Suzhou Industrial Park Biotech Development Co.,Ltd</i> | <br>Zhengbo Song, Doctor & professor, <i>Zhejiang Cancer Hospital</i> | <br>Zhang Ao, Dean, <i>School of Pharmaceutical Sciences, SJTU</i> | <br>Fred Li, Search & Evaluation Director, <i>Novartis</i> | <br>Jiang Zhang, Founder & CEO, <i>LongRiver Investments</i> | <br>Zhu Yonghong, CMO, <i>EpimAb Biotherapeutics</i> | <br>Mingde Xia, Founder, Chairman and CEO, <i>Innolake Biopharm</i> | <br>Yan Wang, VP, <i>RemeGen</i> |
|---|--|---|--|---|---|--|---|

**Technical Forum Planner** (Sort by Confirmation Time)

- |  |  |   |   |   |   |   |  |
|--|--|---|---|---|---|---|--|
| <br>Jing Fan, Founder & CEO, <i>Hopstem Biotechnology</i>                                | <br>Shuang Mei, <i>InBioRay</i> CTO                           | <br>Weiwen Ying, CEO, <i>Ranok Therapeutics (Hangzhou)</i>                                 | <br>Zhihong Lu, Clinical Development/CMO, <i>Shanghai Zhimeng Biopharma,</i>                          | <br>Min Zhao, VP, <i>Innolake Biopharm</i>                                       | <br>Jie Zhang, <i>Biotech</i> Head of Quality  | <br>Hua Ying, Vice President of Qilu institute of innovative pharmaceutical research, Head of <i>Biologics Discovery</i>             | <br>Hao Liu, VP, <i>Qilu Pharmaceutical Research Institute</i>      |
| <br>Rocky Bai, Quality VP, <i>Suzhou Union Biopharm/Junshi Biosciences</i>               | <br>Quanyu Deng, <i>Xilitai</i> Vice General Manager          | <br>Yu Zhang, Executive Director of ADC Chemistry & CMC, <i>DualityBio Ltd</i>             | <br>Deyong Song, Senior Director, <i>Shandong Boan Biotechnology</i>                                  | <br>Stephen Xie, Senior Director, Clinical Development Clinical Translation Lead | <br>Dongmei Han, Deputy General Manager of Drug Product Development, <i>Shanghai Henlius Biotech .</i> | <br>Xuan Wu, Senior Director of Biology, <i>Shanghai EpimAb</i>  | <br>Shi Changhua, Director  |
| <br>Mingyang Gu, GM Assistant, <i>Nanjing Acrolmmune Biopharmaceutical Ltd</i>           | <br>Chang Tan, VP, <i>Ugene-X Biotech .</i>                   | <br>Sheng Wang, NJ Site GM, <i>Nanjing IASO Biotechnology</i>                              | <br>Qi Feifei, Cofounder & CTO, <i>Imunopharm Technology</i>  | <br>Jianwu Fang, SVP, <i>Rona Therapeutics</i>                                   | <br>Bing Du, Professor of <i>East China Normal University &amp; Co-founder of BRL Medicine</i>         | <br>Min Wang, Vice President, <i>PersonGen BioTherapeutics (Suzhou)</i>  | <br>Jingyuan Wu, CMC Director, <i>Shanghai CirCode Biomed</i>       |
| <br>Andrea Wen, Medical Director, <i>Visima Therapeutics</i>                             | <br>Yarong Liu, CEO, <i>Grit Biotechnology</i>                | <br>Shi Zhong, CSO, <i>XLifeS c,Ltd.</i>   | <br>Shengnan Xiang, VP, <i>Starna Therapeutics</i>  | <br>Changyun Xiong, CEO, <i>Ningbo Vigor Biologics</i>                           | <br>Xinpeng Ma, VP, <i>Abogen Biosciences</i>  | <br>Lei Zhao, Executive Director, <i>Cure Genetics</i>   | <br>Li Qing, Director of Oligonucleotides, <i>Junshi Bioscience</i> |
| <br>Wei Zhang, VP, <i>Linno Pharmaceuticals</i>  | <br>Weijun Shen, <i>Center for Translational Innovation</i> | <br>Ge Bai, Vice President of <i>Sinotau</i> , Chief Operating Officer of <i>Glotope</i> | <br>Chris Song, Deputy General Manager & Director of Research, <i>Shanghai Minwei Biotechnology</i> | <br>Yang Gao, Senior Director, Analytical R&D, <i>BeiGene</i>                  | <br>Julia Wu, CMO (Oncology), <i>Fosunpharma Global R&amp;D Center</i>                               | <br>Xiaojun Zhang, Director of the Institute for Pharmaceuticals, <i>Beijing R&amp;D Center, CSPC Pharmaceutical Group Limited</i> | <br>Chen Qianqian, Vice General Manager, <i>Livzon</i>            |
| <br>Guitao Wang, VP, GM Assistant, VP of Research Institute, <i>Coherent Biopharma</i> | <br>Xianbo Zhou, CEO, <i>AstraNeura</i>                     | <br>Yang Jiang, VP of Quality Management, <i>Beijing Innocare Pharma Tech</i>            | <br>Yong-Guo Li, Chairman and CSO, <i>JOYO Pharma</i>   | <br>Vent Qu, CTO, <i>Shenzhen Sciencare Pharmaceutical</i>                     | <br>Haitao Qiao, Managing Director, <i>C Ray Therapeutics (Chengdu)</i>                              | <br>Xiaopei Cui, <i>Huyao Technology</i> Senior Director of Technical Department & Assistant to General Manager                    | <br>Qiang Yu, <i>Shengshi Taike</i> CEO                           |

## BIOCHINA2025 Industrial Forum

Main Forum	Industrial Forum				Roadshow	Closed-door Meeting	Overseas Market	
Exhibition Unveiling	<b>2025 IDC New Drug R&amp;D</b>	<b>2025 GCD Clinical Development Strategy</b>	<b>2025 BIOCHINA X Industry Collaboration and Development Summit</b>	<b>BiO Funding Forum</b>	<b>Investment and Financing Roadshow</b>	Closed-door Meeting on Policies and Regulations		
Opening Ceremony					Small Molecule Innovative Drugs			
C-Level Dialogue	AI Technology Empowering Industry Innovation	Basic Research on Autoimmune Diseases Research Progress	Radiopharmaceuticals - R&D & Collaboration		Peptide Drugs	PI Face to Face - Autoimmune Diseases		International Forum - South Korea Focus
Entrepreneur Interview	XDC Drugs - Development of Novel Conjugated Drugs	Clinical Translation of Autoimmune Diseases			Cell and Gene Therapy	PI Face to Face - Metabolic Diseases		
MNC Interview	Bispecific Antibodies - Platform Innovation	Metabolic Diseases	Peptide Industry Ecosystem Co-Creation		<b>2025 BIOCHINA X Global Commercialization Strategy Forum</b>	Bispecific Antibodies		PI Face to Face - Solid Tumors
MNC Headquarters Strategy Release: The Future of the Chinese Market	Advancements in Universal Cell Therapy Research	CNS Disorders	ADC Industry Ecosystem Co-Creation	Payment and Insurance	ADC (Antibody-Drug Conjugates)	PI Face to Face - Hematologic Tumors		
				Domestic Sales Collaboration	Innovative Technology Tools (e.g., AI)	Research Translation Closed-door Meeting		
				Overseas Market Sales	Upstream Raw Material Suppliers			
Pharma Strategy Release	Gene Editing Platform Technology	ADC	Pharmaceutical Company Collaboration and Translation	Mergers and Acquisitions Integration	Life Sciences Service Providers	<b>Data Release</b>	Other International Markets Focus (India, Japan, EAEU, Middle East, US, etc)	
	Breakthroughs in Small Nucleic Acid Delivery Platforms	Synthetic Lethality	Combination Therapy	<b>Bio BD Forum</b>	Others			
	mRNA - Breakthroughs in New Technologies	Cell Therapy			<b>University Technology Transfer Roadshow</b>			

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
<b>Main Forum</b>			
09:00-11:30	09:00 - 09:20 Exhibition Unveiling 09:20AM -09:30AM Opening Ceremony Speaker : Dong Chen, Academician of Chinese Academy of Sciences, Dean of Medical School of Westlake University 09:30 -10:00 C-Level Dialogue Speaker : Sun Piaoyang, Chairman, Hengrui Pharma 10:00-11:00 Entrepreneur Interview Speaker : Aimin HUI, President&CEO, EnCureGen Pharma Guangzhou Limited 11:00 -11:30 C-Level Dialogue Speaker : Yong Jun Liu, Executive President, President Global R&D, CSPC PHARMA.	09:00-10:00 MNC Interview  10:00-11:00 MNC Headquarters Strategy Release: The Future of the Chinese Market (Three 20-minute sessions)	Exhibition time/BioPartnering
12:00-14:00	Exhibition time/BioPartnering	12:00-14:00 MNC Headquarters Strategy Release: The Future of the Chinese Market (Six 20-minute sessions)	
15:00-17:00	Exhibition time/BioPartnering	15:00-17:00 Pharma Strategy Release ((Six 20-minute sessions))	

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
09:00-11:00	Exhibition time/BioPartnering	<p align="center"><b>2025 IDC New Drug R&amp;D Impact</b></p> <p><b>AI Technology Empowering Industry Innovation</b>            09:00-09:20 Presentation: The Application of AI in the Design of Large Molecule Drugs            09:20-09:40 Presentation: AI helps discover disease mechanisms and empowers new drug development            09:40-10:00 Presentation: Artificial intelligence assisted drug target discovery            10:00-11:00 Panel Discussion:Full chain AI empowers new drug innovation and optimization  <b>Speaker :</b> Feng Ren, co-CEO &amp; CSO, Insilico Medicine Ltd</p>	<p><b>Breakthroughs in Small Nucleic Acid Delivery Platforms</b>            09:00-09:20 Presentation: Progress in Non Liver Targeted Delivery Platforms            09:20-09:40 Presentation: Development of new delivery vehicles            09:40-10:20 Panel Discussion:Innovation in delivery platform            10:20-11:00 Panel Discussion:Differentiated Small Nucleic Acid Pipeline Layout Strategy  <b>Speaker :</b> Michael Yin, Chairman, Suzhou Industrial Park Biotech Development Co.,Ltd            Rongkuan Hu ,Starna Therapeutics,Founder &amp; CEO            Peter Zhang, Chairman &amp; CSO, Suzhou GenePharma . Cui Wenhao, founder of Youjia Biotech</p>
12:00-14:00	<p><b>Bispecific Antibodies - Platform Innovation</b>  <b>Planner:</b> Zhihong Chen,CEO,Curon Biopharmaceutical (Shanghai) Ltd,            12:00-12:20 Presentation: Clinical trial of dual antibody project            12:20-12:40 Presentation: Progress of Multi Antibody Platform            12:40-13:20 Panel Discussion:Establishment of Dual Resistance Industry Ecology            13:20-14:00 Panel Discussion: Establishment and Transformation of Innovation Platforms  <b>Speaker :</b> Chengbin Wu, CEO, Shanghai EpimAb Biotherapeutics .            Hongtao Lu, Co-founder&amp;CSO, Elpiscience            Wenzhi Tian, Chairman, CEO &amp; CSO, ImmuneOnco Biopharmaceuticals (Shanghai) .            Zhenhao Zhou, CEO, Chimagen Biosciences, Ltd.            Jieyu Zou, Partner, Lily AsiaVentures            Hu Mingxiu, Senior Vice President of Kangfang Biopharma.</p>	<p><b>Advancements in Universal Cell Therapy Research</b>  <b>Planner:</b> Zonghai Li, Chairman&amp;CEO, CARsgen            12:00-12:20 Presentation: Development of Car-T technology platform in vivo            12:20-12:40 Presentation: Car NK product development            12:40-13:20 Panel Discussion:Main challenges and solutions for universal cell therapy            13:20-14:00 Panel Discussion:Integration and Innovative Application of iPSC Technology  <b>Speaker :</b> Jing Fan, Founder &amp; CEO, Hopstem Biotechnology            Biao Zheng, CEO, BRL Medicine .            Liqun Wang, Founder, Chairman and CEO, Neukio Biotherapeutics            Xiang Li (Michael Lee), Ph.D., Founder &amp; CEO, XellSmart</p>	<p><b>mRNA - Breakthroughs in New Technologies</b>            12:00-12:20 Presentation: Circular RNA development            12:20-12:40 Presentation: CRISPR gene editing therapy encoded by mRNA            12:40-13:00 Presentation: AI technology empowers mRNA            13:00-14:00 Panel Discussion:mRNA Tech breakthroughs in non-communicable disease indications  <b>Speaker :</b> Zhefan Yuan, CEO&amp;CTO, Nanjing CybernaX Biomedical Technology .            Chris Lai, Co-founder &amp; CEO of METiS Pharmaceuticals</p>
15:00-17:00	<p><b>XDC Drugs - Development of Novel Conjugated Drugs</b>  <b>Planner:</b> Mingde Xia, Founder, Chairman, and CEO ,Innolake Biopharm            15:00-15:20 Presentation: Development Strategy for Dual Anti ADC            15:20-15:40 Presentation: AOC Development Strategy            15:40-16:00 Presentation: PDC Development Strategy            16:00-16:20 Presentation: Development strategy of PROTAC coupled drugs            16:20-17:00 Panel Discussion:Everything is interconnected, innovative molecular design  <b>Speaker :</b> Lianshan Zhang, Board Director&amp;Vice President, Jiangsu Hengrui Pharmaceuticals .            Ziyue Sui,CEO,Lepu Biopharma Co.,Ltd.</p>	<p><b>Gene Editing Platform Technology</b>            15:00-15:20 Presentation: The latest technological innovation in CRISPR gene editing            15:20-15:40 Presentation: Application of AI+gene editing technology            15:40-16:00 Presentation: Development of gene edited T cell products            16:00-16:20 Presentation: Development of gene edited NK cell products            16:20-17:00 Panel Discussion:Gene editing technology innovation, unlimited potential  <b>Speaker :</b> Wei Wensheng, Professor at the School of Life Sciences, Peking University.</p>	Exhibition time/BioPartnering

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
2025 Global Clinical Development Strategy Conference for GCD Innovative Drugs			
09:00-11:00	Exhibition time/BioPartnering	<p><b>Synthetic Lethality</b>  <b>Planner: Linong Ji, Director of the Department of Endocrinology and Metabolism, Peking University People's Hospital</b>            09:00-09:20 Presentation: The unmet clinical needs of metabolic drugs from a clinical perspective            09:20-09:40 Presentation: MNC perspective on the development strategy of metabolic drugs in China            09:40-10:00 Presentation: Application of innovative technologies from the perspective of Chinese pharmaceutical companies in the development of metabolic drugs            10:00-11:00 Panel Discussion: Multi party collaboration to promote the development and transformation of metabolic drugs</p>	<p><b>Metabolic Diseases</b>  <b>Planner: Zhengbo Song, Doctor, professor, Zhejiang Cancer Hospital</b>            09:00-09:20 Presentation: Clinical progress in the development of synthetic lethal drugs            09:20-09:40 Presentation: Progress in clinical development of 18A inhibitors            09:40-10:00 Presentation: The world's first PRMT1 drug development - targeting the epigenetic regulation mechanism of a new generation of tumors  <b>Hailing Wu, CEO, Cytosinlab Therapeutics .</b>  <b>Mingxi Li, CEO, Apeiron</b>            10:00-10:20 Presentation: Progress in clinical development of PRMT5            10:20-10:40 Presentation: Sponsorship speaking opportunities open            10:40-11:00 Q&amp;A  <b>Speaker : Wang Haidan, Chief Medical Officer at Qinhoo Pharmaceuticals</b>  <b>Hailing Wu, CEO, Cytosinlab Therapeutics .</b>  <b>Mingxi Li, CEO, Apeiron</b></p>
12:00-14:00	<p><b>Basic Research on Autoimmune Diseases Research Progress</b>            12:00-12:20 Presentation: Molecular and cellular mechanisms of autoimmune diseases            12:20-12:40 Presentation: Discovery of new targets for autoimmune diseases            12:40-13:00 Presentation: The potential of gene editing technology in the treatment of autoimmune diseases            13:00-13:20 Presentation: The application and challenges of stem cell therapy in repairing damaged tissues and regulating immune responses            13:20-14:00 Panel Discussion: Exploration of the Path from Basic Research to Clinical Translation of Autoimmune Diseases</p>	<p><b>CNS Disorders</b>            12:00-12:20 Presentation: Alzheimer's disease (AD) does not meet clinical needs            12:20-12:40 Presentation: Alzheimer's disease drug development            12:40-13:00 Presentation: CNS pathogenic mechanism research empowers drug innovation research and development            13:00-13:40 Panel Discussion: CNS Product Differentiation Development Strategy            13:40-14:20 Panel Discussion: New therapies and mechanisms empower innovative development of CNS drugs  <b>Speaker : Wang Xining, Head of the Central Nervous System Medical Department at Hengrui Medicine.</b>  <b>Sarah Lu, Chief Medical Officer, Shanghai Zhimeng Biopharma, .</b>  <b>Joan (Huaqiong) Shen, Founder and CEO, NeuShen Therapeutics</b>  <b>Yelin Chen, Principal Investigator, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences</b>  <b>Gary Tong, VP, Takeda</b>  <b>Huafang Li, Executive Director, Clinical Trial Institute, Shanghai Mental Health Center</b>  <b>Jin-Tai Yu, Chief Physician, Huashan Hospital, Fudan University</b></p>	<p><b>Cell Therapy</b>  <b>Planner: Chen Jie, IASO BIO, CMO</b>            12:00-12:20 Presentation: In vivo cell therapy clinical practice  <b>Speaker : XiaoChen Wang, VP, BRL Medicine .</b>            12:20-13:00 Panel Discussion: Clinical translation and regulation of universal cell therapy  <b>Speaker : XiaoChen Wang, VP, BRL Medicine .</b>            13:00-13:20 Presentation: Cell therapy breaks through solid tumors            13:20-14:00 Panel Discussion: How to improve the clinical accessibility of cell therapy</p>

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
	2025 Global Clinical Development Strategy Conference for GCD Innovative Drugs		
15:00-17:00	<p><b>Clinical Translation of Autoimmune Diseases</b>  <b>Planner:</b> <a href="#">Huji Xu, Professor, Shanghai Changzheng Hospital</a>            15:00-15:20 Presentation: Clinical progress of dual antibodies in autoimmune diseases            15:20-15:40 Presentation: Clinical progress of cell therapy in autoimmune diseases            15:40-16:10 Discussion: From the perspective of clinical PI, discussing the unmet need for self exemption            16:10-17:00 Panel Discussion: From the perspective of CMO, the difficulties in clinical development of self administered drugs  <b>Speaker:</b> <a href="#">Goh Aik Han, SVP&amp;CMO, Simcere Pharmaceutical Group Limited</a>  <a href="#">Anbo Xiang, President of Clinical Division &amp; CMO of Non-oncology, CSPC Pharmaceutical Group</a>  <a href="#">Chen Jie, CMO, IASO BIO</a></p>	<p><b>ADC</b>  <b>15:00-15:20 Presentation: Clinical Progress of ADC Drugs</b>  <b>Speaker:</b> <a href="#">Tongtong Xue, Founder, Chairman &amp; CEO, Yilian Biotech</a>  <b>15:20-15:40 Presentation: Global Clinical Development Strategy for Efficient ADC Drugs</b>  <b>Speaker:</b> <a href="#">Junfang Xu, Chief Medical Officer, East China Pharmaceutical Group</a>  <b>15:40-16:00 Presentation: Safety Management of ADC Drugs Across Multiple Cancer Types</b>  <b>16:00-17:00 Panel Discussion: Collaborating to Accelerate ADC Drug Development</b>  <b>Speakers:</b>  <a href="#">Lin Shen, Director of Digestive Oncology, Peking University Cancer Hospital</a>  <a href="#">Tongtong Xue, Founder, Chairman &amp; CEO, Yilian Biotech</a>  <a href="#">Junfang Xu, Chief Medical Officer, East China Pharmaceutical Group</a></p>	Exhibition time/BioPartnering





# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
2025 BIOCHINA X Industry Collaboration and Development Summit			
09:00-11:00	Exhibition time/BioPartnering	<p><b>Co-Building the ADC Industry Ecosystem</b>                      Planner: Zhongyuan Zhu, Founder &amp; CEO, Ying'en Biotech                      09:00-09:20 Presentation: Global Patent Landscape Analysis of ADC Drug Linkers and Payloads                      09:20-09:40 Presentation: R&amp;D and Clinical Development of ADC Drugs                      09:40-10:00 Presentation: CMC and BLA Production of ADC Drugs                      10:00-10:20 Presentation: Commercialization Strategy of ADC Drugs                      10:20-11:00 Panel Discussion: How to Build a Global ADC Drug Industry Ecosystem</p>	<p><b>Early clinical development strategies</b>                      Planner: Yonghong Zhu, CMO, EpimAb Biotherapeutics                      09:00-09:20 Case                      09:20-10:00 Panel Discussion:How to tell clinical stories about MNCs going abroad                      Host : Jolee Li, Partner, Langsheng Investment                      Speaker: Xu Qian, Senior Vice President at Gensai Pharmaceuticals                      Vivian Huang,CMO,CSPC                      10:00-10:20 Case                      10:20-11:00 Panel Discussion:How to tell the story of New Co's cooperation with VC overseas                      Host : Yonghong Zhu, CMO, EpimAb Biotherapeutics                      Speaker :Xiao, Shen, Chief Medical Officer, 3D Medicines</p>
12:00-14:00	<p><b>Radiopharmaceuticals - R&amp;D &amp; Collaboration</b>                      Planner: Fred Li, Search &amp; Evaluation Director, Novartis  <b>Radiopharmaceuticals - R&amp;D &amp; Collaboration</b>                      Planner: Fang Li, Director of Search &amp; Evaluation, Novartis Biopharmaceuticals  <b>Innovation and Application of Radiopharmaceutical Technologies</b>                      12:00-12:20 Presentation: Topic Confirmation                      Speaker: Marcel Reichen, Executive Director, Search &amp; Evaluation, Radioligand Therapy, Novartis                      12:20-12:40 Presentation: Topic Confirmation                      Speaker: Fangyong Du, Chief Scientific Officer, Tongrui Biotech                      12:40-13:00 Presentation: Topic Confirmation                      Speaker: Maiqing Liao, Chief Executive Officer, NuZhou Pharmaceuticals                      13:00-13:20 Presentation: Topic Confirmation                      Speaker: Tao Xu, Chief Executive Officer, Zhihuo Biotech                      13:20-13:40 Presentation: Topic Confirmation                      Speaker: Yilong Li, Vice President, Zhongsheng Quantipe Pharmaceuticals                      13:40-14:00 Presentation: Topic Confirmation</p>	<p><b>Breaking the Path for University-Industry Collaboration, Empowering Industrial Innovation</b>                      Planner: Ao Zhang, Dean, School of Pharmacy, Shanghai Jiao Tong University                      12:00-12:00 Case Sharing: From Basic Research to Product Launch Journey                      12:20-12:40 Case Sharing: Collaboration between School of Pharmacy, Shanghai Jiao Tong University and Shanghai Pharmaceuticals, and Future Plans                      Speaker: Feng Qian, Professor, Shanghai Jiao Tong University                      12:40-13:00 Presentation: Accelerating the Translation of Basic Research into Industry from a Clinical Perspective                      13:00-14:00 Panel Discussion: University-Industry Collaboration, Co-building an Innovative Ecosystem                      Host: Ao Zhang, Dean, School of Pharmacy, Shanghai Jiao Tong University                      Speakers:                      Yidong Zhu, Executive Vice President, Innovation Drug R&amp;D Center, Qilu Pharmaceutical                      Dajun Yang, Co-founder, Chairman and CEO of Ascentage Pharma</p>	<p><b>Combination Therapy</b>                      12:00-12:20 Report : Combination therapy strategy of immune checkpoint inhibitors                      12:20-12:40 Presentation: Combination therapy strategies targeting specific signaling pathways                      12:40-13:00 Presentation: Collaborative research and development of joint drug strategies on technology platforms                      13:00-13:20 Presentation: Combination therapy strategy for drug resistance                      13:20-14:00 Panel Discussion:How to improve the efficacy and market competitiveness of new drugs through combination therapy                      Speaker :Xiao, Shen, CMO, 3D Medicines                      STEVE CHIN, CMO, MediLinl Therapeutics</p>

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
	<b>2025 BIOCHINA X Industry Collaboration and Development Summit</b>		
15:00-17:00	<p><b>Co-building the Radiopharmaceutical Industry Ecosystem</b>            15:00-16:00 Panel Discussion: How to Translate Scientific Research into a Company in the Radiopharmaceutical Field  <b>Speakers:</b>            Marcel Reichen, Executive Director, Search &amp; Evaluation, Radioligand Therapy, Novartis            Andreas Kjaer, Professor, Rigshospitalet &amp; University of Copenhagen, Co-founder of Curasight            Marie-Lyn Horlacher, Partner, Oliver Wyman            Tao Yu, Investment Director, Eli Lilly Asia Fund            Zhibo Liu, Professor, Peking University, Co-founder of Boyue Chuanghe</p> <p>16:00-17:00 Panel Discussion: Exploring Successful Collaborations from Different Perspectives in the Radiopharmaceutical Field  <b>Speakers:</b>            Marcel Reichen, Executive Director, Search &amp; Evaluation, Radioligand Therapy, Novartis            Dadong Chen, Managing Director, BFC            Oliver Fröscheis, Senior Vice President, Corporate Development, Full-Life            Ge Bai, Chief Operating Officer, Guotong New Drug            Dong Chen, Vice General Manager of BD, Hengrui Medicine, Head of Global Business Development Operations, Head of Business Development China</p>	<p><b>Four-in-One Translation Strategy for Early Research in Antitumor Drugs</b>  <b>Host:</b> Danyi Wen, Chairman &amp; CEO, Shanghai Lidi Biotech            15:00-15:10 Presentation: Overview of the Four-in-One Translation Strategy  <b>Speaker:</b> Jin Li, Dean, Shanghai Gaobo Oncology Hospital, China Pharmaceutical University            15:10-15:30 Presentation: Translational Application of Functional Testing in Clinical Indication Exploration  <b>Speaker:</b> Danyi Wen, Chairman &amp; CEO, Shanghai Lidi Biotech            15:30-15:50 Presentation: Application of QSP Models in Early Translational Research and Drug Development Decisions  <b>Speaker:</b> Chen Zhao, Professor, Nanjing Medical University            15:50-16:10 Presentation: Role of Clinical Quantitative Pharmacology in New Drug R&amp;D and Regulatory Review  <b>Speaker:</b> Yaning Wang, Founder, Ruiningkang Biopharma            16:10-16:30 Presentation: Application of Innovative Bayesian Statistical Methods in New Drug R&amp;D  <b>Speaker:</b> Yuan Ji, Professor of Biostatistics, University of Chicago; Director, Clinical Trial Excellence Center            16:30-16:50 Presentation: Innovative Clinical Research Supporting New Drug Discovery  <b>Speaker:</b> Min Zhang, Senior Director, Shida (Shanghai) Pharmaceutical Technology .            16:50-17:00 Summary and Discussion  <b>Speaker:</b> Jin Li, Dean, Shanghai Gaobo Oncology Hospital, China Pharmaceutical University</p>	Exhibition time/BioPartnering



# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
	<b>BIOFUNDING Forum</b>	<b>International Forum - China-Korea Forum</b>	<b>Bio BD Forum</b>
09:00-11:00	<b>Exhibition time/BioPartnering</b>	<b>09:00-09:20 Presentation: Korea Bio Ecosystem: Overview and Regulatory Landscape</b> <b>09:20-10:00 Panel Discussion: BD &amp; Licensing Cooperation Opportunities</b> <b>10:00-10:30 Dialogue: Sharing China-Korea BD Deal Cases</b> <b>10:30-11:00 Panel Discussion: Innovative Collaboration Opportunities and Challenges</b>	09:00-09:20 Presentation: 2024 Global BD Deal Review and Trend Analysis 09:20-10:00 Panel Discussion: Global Vision, Global Focus Host: <a href="#">Mingjiu Chen, Chairman &amp; CEO, BioOceanX</a> Speakers: <a href="#">Xiaoqiang Kang, Founder, Chairman &amp; CEO, Vailis Biotech</a> 10:00-11:00 Panel Discussion: MNCs and Pharma Discuss BD Deals with Chinese Biotech - What Are We Looking For? Host: <a href="#">Yueyue Wang, Managing Partner, Tianchao Capital</a> Speakers: <a href="#">Yinghui Yu, Senior Director, Global BD, Johnson &amp; Johnson</a> <a href="#">Xin Wang, Head of Business Development, Asia Pacific, Sobi</a> <a href="#">Bingke Yu, Head of External Innovation Center, Greater China, Boehringer Ingelheim</a> <a href="#">Yanan Xu, Head of Global External Innovation Collaboration, China, Takeda Pharmaceuticals</a> <a href="#">Hao Jiang, Executive Director, CSPC Pharmaceutical Group</a> 12:00-12:40 Panel Discussion: BD Deals Before and After Announcements: Negotiations and Dialogue Speakers: <a href="#">Ping Cao, CBO, Everest Medicines</a> <a href="#">Ling Tong, BD Head / VP, Buchang Pharmaceutical</a> <a href="#">Tingke Tang, General Manager, BD Headquarters, Livzon Pharmaceutical Group</a> <a href="#">Qifeng Han, Head of Global BD &amp; Licensing, Greater China, Boehringer Ingelheim</a>
12:00-14:00	<b>Planner: <a href="#">Jiang Zhang, LongRiver Investments Founder &amp; CEO, LongRiver Investments</a></b> <b>12:00-13:00 Panel Discussion: Dual currency fund investment strategy</b> <b>13:00-14:00 Panel Discussion: Insurance LP Investment Strategy</b>	<b>2025 BIOCHINA X Global Commercialization Strategy Forum</b> <b>Overseas Market Sales</b> <b>12:00-12:40 Panel Discussion: Overseas market sales strategy</b> <b>Speaker :</b> <b><a href="#">Jason Yang, CStone, Chief Executive Officer, President of R&amp;D</a></b> <b><a href="#">Jason Zhu, CEO, Henlius</a></b> <b>12:40-13:00 Presentation: Japanese market strategy</b> <b>Speaker: <a href="#">Jason Zhu, CEO, Henlius</a></b> <b>13:00-13:20 Presentation: European market strategy</b> <b>13:20-13:40 Presentation: Southeast Asian market strategy</b> <b>13:40-14:00 Presentation: African Market Strategy</b> <b>Speaker: <a href="#">Mina Adel, Consultant, IAVI</a>; <a href="#">Africa CDC</a></b> <b>14:00-14:20 Presentation: South American market strategy</b>	<b>International Forum - China-Russia Forum</b> 13:00-13:05 Opening Remarks 13:05-13:25 Presentation: Overview of the Russian Pharmaceutical Industry 13:25-13:45 Presentation: Interpretation of Russian Drug Registration and Distribution Regulations 13:45-14:05 Presentation: Detailed Explanation of the Eurasian Economic Union Drug Registration Policies and Processes1 4:05-14:35 Panel Discussion: China-Russia Biopharma BD & Licensing Cooperation Opportunities 14:35-15:00 Roadshow: Russian Biopharma Companies' Supply Chain and Product Services Showcase
15:00-17:00	<b>15:00-16:00 Panel Discussion: State owned LP investment strategy</b> <b>16:00-17:00 Panel Discussion: Post investment management</b>	<b>Mergers and Acquisitions Integration</b> <b>15:00-15:20 Case1</b> <b>15:20-15:40 Case2</b> <b>15:40-16:20 Panel Discussion: The trend and challenges of mergers and acquisitions in the field of biomedicine</b> <b>16:20-17:00 Panel Discussion: The role of innovative technology in biopharmaceutical mergers and acquisitions</b>	

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
09:00-10:00	Exhibition time/BioPartnering	Closed-door Meeting on Policies and Regulations	PI Face to Face - Hematologic Tumors
10:00-11:00			
12:00-13:00	Closed-door Meeting on Policies and Regulations	PI Face to Face - Metabolic Diseases	Exhibition time/BioPartnering
13:00-14:00		PI Face to Face - Solid Tumors	
15:00-16:00	PI Face to Face - Autoimmune Diseases	Research Translation Closed-door Meeting	
16:00-17:00	Overseas Market		



# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
	<b>Investment and Financing Roadshow</b> Mentor: Jayson Lee, LongRiver Investments Partner, LongRiver Investments		<b>University Technology Transfer Roadshow</b> Co-organizers: Suzhou Science and Technology Bureau, National Center for Biotechnology Innovation.
09:00-10:00	Exhibition time/BioPartnering	09:00-10:00 mall Molecule Innovative Drugs 15mins-4sessions Project : EP4 receptor antagonist KF-0210 promotes cartilage growth for the treatment of osteoarthritis Fund B	<b>09:00-14:00 University Technology Transfer Roadshow</b> Host: Bin Li, Researcher, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine <b>Project Title:</b> mRNA Sequence Optimization Technology to Enhance Protein Expression and Reduce Production Costs
10:00-11:00		10:00-11:00 Peptide Drugs 15mins-4sessions	<b>Roadshow Request:</b> Patent Transfer, Cooperative Development Presenter: Yi Kuang, Associate Professor, Hong Kong University of Science and Technology
12:00-13:00	12:00-13:00 Antibody-Drug Conjugates 15mins-4sessions	12:00-13:00 Innovative Technology Tools (e.g., AI) 15mins-4sessions	<b>Project Title:</b> Small Nucleic Acid Drugs for Metabolic-Associated Fatty Liver Disease
13:00-14:00	13:00-14:00 ADC 15mins-4sessions	13:00-14:00 Life Sciences Service Providers 15mins-4sessions	<b>Roadshow Request:</b> Cooperative Development Presenter: Xuemei Tong, School of Pharmacy, Shanghai Jiao Tong University <b>Project Title:</b> Immune Synapse Simulation with Biomaterials: Using Artificial Cells to Dynamically Activate T Cells and NK Cells <b>Roadshow Request:</b> Seeking Technical and Business Partners, Sales Channels, Regional Agents, Product Promotion, Fundraising & Entrepreneurship Presenter: Zhiming Liu, Co-founder & CEO, Huanjing Biotech <b>Project Title:</b> Topic Confirmation Presenter: Jinqiang Wang, Researcher, Zhejiang University <b>Project Title:</b> Topic Confirmation Presenter: Yunlong Huo, Tenured Associate Professor, School of Life Sciences and Technology, Shanghai Jiao Tong University <b>Project Title:</b> Topic Confirmation Presenter: Zhi Xie, Professor, Zhongshan Ophthalmic Center, Sun Yat-sen University <b>Project Title:</b> Topic Confirmation Presenter: Liqin Zhang, Researcher/Assistant Professor, Peking University <b>Project Title:</b> Topic Confirmation Presenter: Fubin Li, Shanghai Jiao Tong University School of Medicine, Immunology Institute <b>Project Title:</b> Topic Confirmation Presenter: Zhenhua Ren, Researcher, Changping Laboratory Project Title: Topic Confirmation Presenter: Yun Wang, Professor, Fudan University
15:00-17:00	15:00-16:00 Cell and Gene Therapy 15mins-4sessions 16:00-17:00 Nucleic Acid Drugs 15mins-4sessions	15:00-17:00 others 15mins-8sessions	Exhibition time/BioPartnering

# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
<b>Data Release</b>			
09:00-11:00	Exhibition time/BioPartnering	<p>Nucleic Acid Drugs            09:00-09:20 Presentation: A Study on the Efficacy and Safety of a Novel Oligonucleotide Therapy in ALS: A FIH Trial  <b>Speaker</b> : <a href="#">Lorenzo Xie,CSO,Ractigen Therapeutics</a>            09:20-09:40 Presentation: Topic to be confirmed  <b>Speaker</b> : <a href="#">Vicky Song,CMO,Abogen Biosciences (Shanghai)</a> .            09:40-10:00 Presentation: Topic to be confirmed  <b>Speaker</b> : <a href="#">Tao Guan, Co-founder&amp;CEO, Hygieia Pharmaceutical Co.,Ltd.</a>            10:00-10:20 Presentation: Topic to be confirmed  <b>Speaker</b> : <a href="#">Qunsheng Ji, CEO, Sirius Therapeutics</a></p>	<p><b>Small molecule innovative drugs</b>            09:00-09:20 Presentation: The discovery and the preclinical evaluation of oral cyclic peptide PCSK9 inhibitors  <b>Speaker</b> : <a href="#">Chester Yuan,Co-Funder/CSO,Shenzhen Sungening Biologicals Ltd.</a>            09:20-09:40 Presentation: Topic to be confirmed  <b>Speaker</b> : <a href="#">Jintao Zhang, Ph.D., CEO, JS InnoPharm (Shanghai) Ltd</a>            09:40-10:00 Presentation: Topic to be confirmed  <b>Peptide drugs</b>            10:00-10:20 Presentation: The discovery of oral cyclic peptide PCSK9 inhibitors  <b>Speaker</b> :            10:20-10:40            Presentation:The discovery and the preclinical evaluation of oral cyclic peptide PCSK9 inhibitors            10:40-11:00 Presentation: Topic to be confirmed</p>



# BIOCHINA2025 Industrial Forum

Date	March 13th	March 14th	March 15th
<b>Data Release</b>			
12:00-14:00	<p><b>Cell therapy</b>                      12:00-12:20 Presentation: Clinical progress of HBV TCR-T cells in the treatment of hepatitis B virus related diseases                      Speaker : <a href="#">Tingting WANG, COO&amp;CMO, Lion TCR</a>                      12:20-12:40 Presentation: Standing at Thirty: The Path of Mesenchymal Stem Cell Transformation?                      Speaker : <a href="#">Yu Zhang, SVP&amp;CSO, Vcanbio Cell &amp; Gene Engineering Corp., Ltd.</a>                      12:40-13:00 Presentation: Treatment of autoimmune diseases with Triarm's innovative CD19-targeted CAR T cells                      Speaker : <a href="#">Jinhua Lu, Co-founder and CSO, TriArm Therapeutic Co.</a>                      13:00-13:20 Presentation: Outstanding safety and efficacy data of Immunofocus IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced digestive system tumors                      Speaker : <a href="#">Crystal Sun, Immunocofo Biotech founder, chairman &amp; CEO</a>                      13:20-13:40 Presentation: Topic to be confirmed                      Speaker : <a href="#">Jun Wei, CEO, Igegene</a>                      13:40-14:00 Presentation: Topic to be confirmed</p>	<p><b>Bispecific antibodies Drugs</b>                      12:00-12:20 Presentation: HBM7020, a T-cell engager bispecific, demonstrated strong B-cell depletion in NHP                      12:20-12:40 Presentation: Topic to be confirmed                      Speaker : <a href="#">Xiaolu Tao, President of Harbour Therapeutics, Harbour BioMed</a>                      12:40-13:00 Presentation: Novel bi/tri-specific NK cell engagers for oncology and autoimmune diseases                      Speaker : <a href="#">Chao Tu, Co-founder, President &amp; CEO, Biomissile Pharmaceuticals</a>                      13:00-13:20 Presentation: Topic to be confirmed                      Speaker : <a href="#">Mingjiu Chen, Founder, President &amp; CEO, Biosion</a> ,                      13:20-13:40 Presentation: Topic to be confirmed                      13:40-14:00 Presentation: Topic to be confirmed</p>	<p><b>other drugs</b>                      12:00-12:20 Presentation: Drug Delivery Values of Exosomes in Tissue Regeneration and Cosmetics                      Speaker : <a href="#">Ke Xu, CEO, VesiCURE Therapeutics</a> .                      12:20-12:40 Presentation: First disclosure of FC335 investigator initiated clinical trial (IIT) results                      Speaker : <a href="#">Ning Xi, CEO, AXL</a>                      12:40-13:00 Presentation: Topic to be confirmed                      Speaker : <a href="#">Tan Wei, Head of Research and External Partnerships for the China Region at Clover Pharmaceuticals</a>                      13:00-13:20 Presentation: Topic to be confirmed                      13:20-13:40 Presentation: Topic to be confirmed                      13:40-14:00 Presentation: Topic to be confirmed</p>
15:00-17:00	<p><b>Gene therapy</b>                      15:00-15:20 Presentation: Topic to be confirmed                      15:20-15:40 Presentation: Topic to be confirmed                      Speaker : <a href="#">Guangzuo Luo, CEO, BIONCE Biotechnology</a>                      15:40-16:00 Presentation: Topic to be confirmed                      16:00-16:20 Presentation: Topic to be confirmed                      Speaker : <a href="#">Hanming Wang, Vice President, Binhui Biopharmaceutical</a>                      16:20-16:40 Presentation: Topic to be confirmed                      16:40-17:00 Presentation: Topic to be confirmed</p>	<p><b>ADC Drugs</b>                      15:00-15:20 Presentation: ADC data in advanced solid tumor stage 1                      Speaker : <a href="#">Rachel Shi, CMO, Genequantum Healthcare</a>                      15:20-15:40 Presentation: Topic to be confirmed                      15:40-16:00 Presentation: Topic to be confirmed                      16:00-16:20 Presentation: Topic to be confirmed                      16:20-16:40 Presentation: Topic to be confirmed                      16:40-17:00 Presentation: Topic to be confirmed</p>	Exhibition time/BioPartnering



## BIOCHINA 2025 Technology Forum & Brainstorming

March 13th	March 14th	March 15th
ADC Innovation and Development Technology Forum [R&D]	ADC Innovation Forum [Process Quality]	Biopharmaceutical Innovation Process Development Technology Forum [Process]
Biopharmaceutical Innovation Process Development Technology Forum [QA]	Biologics Innovation Forum [R&D]	Other Biologics Innovation Forum [R&D]
Bioprocessing & Plants construction Management Forum [Production Management]	Nuclear Medicine Innovation Forum	Biopharmaceutical Production & Engineering Management Forum [Production Management]
Biologics Innovation Development Technology Forum [Formulations] Pharmaceutical Packaging & Administration Forum	Peptide Drug Innovation Forum	Peptide Drug Innovation Forum
Biopharmaceutical Industry Supply Chain Forum	Cell Therapy Innovation Forum [R&D]	Cell Therapy Innovation Forum [R&D]
Cell Therapy Innovation Forum [Process and Quality Manufacturing]	Cell Therapy Innovation Forum [Process and Quality Manufacturing]	Gene Therapy Innovation Forum
Small RNA Therapeutics Innovation Forum	mRNA Innovation Forum	University Laboratory Construction and Operations Forum
Small Molecule Drug Innovation Forum	Small Molecule Drug Innovation Forum	Small Molecule Drug Innovation Forum
[Brainstorming] Drug Development Based on Popular Targets	[Brainstorming] New Drug Development Strategies Based on Different Indications	[Brainstorming] Preclinical Evaluation Case Study
[Brainstorming] Process Optimization	[Brainstorming] Process Development and Optimization	[Brainstorming] Quality System and Quality Analysis
[Brainstorming] Regulatory Affairs and Submission	[Brainstorming] Production Management and Optimization	[Brainstorming] Production Facility and Engineering Design



# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>ADC Innovation and Development Technology Forum [R&amp;D]</b>	<b>ADC Innovation Forum [Process Quality]</b>	<b>Biopharmaceutical Innovation Process Development Technology Forum [Process]</b>
09:00-10:00	Exhibition time/BioPartnering	<p><b>Process Development and Quality Control for ADC</b>                      Planner: Shi Changhua, Director, Shanghai Hengrui pharmaceuticals                      09:00-09:20 Presentation: General Consideration for ADC Process Development                      Speaker: lin Wenfeng, Assistant Director, Shanghai Hengrui pharmaceuticals                      09:20-09:40 Presentation: Quality Control Strategy for ADC                      Speaker: Sun Xiaolan, QC Senior Director, Shanghai Hengrui Pharmaceuticals Co.LTD                      09:40-10:00 Presentation: Characterization of ADC by CE-SDS                      Speaker: Ji Guanghui, Research Scientist, Shanghai Hengrui pharmaceuticals</p>	<p><b>Challenges and Innovations in Downstream Process</b>                      Planner: yan yang, Director, Henlius                      09:00-09:20 Presentation: Removal and Identification Strategy for Host cell proteins                      Speaker: yuxia ren, group leader, Henlius                      09:20-09:40 Presentation: Sharing the Process Characterization of Downstream                      Speaker: Chen Ruijie, PDD Senior manager, Shanghai Henlius Biotech, .                      09:40-10:00 Presentation: Digitalization and Intelligentization: New Trends in Biopharmaceutical Process development                      Speaker: Ran Chen, Shanghai Henlius Biotech, ., Associate Director of Process Development Downstream</p>
10:00-11:00	<p><b>Dual anti ADC from early research to CMC</b>                      Planner: Min Zhao, VP, Innolake Biopharm                      10:00-10:20 Presentation: Preclinical development of dual antibody ADC drugs                      Speaker: Yushuan Shang, E. Director, Innolakebio                      10:20-10:40 Presentation: CMC Developability of Bispecific ADCs                      Speaker: Innolakebio, Vice Director of CMC                      10:40-11:00 Presentation: Topic to be confirmed</p>	<p><b>Process Development and Quality Control for ADC</b>                      Planner: Yu Zhang, Executive Director of ADC Chemistry &amp; CMC, DualityBio Ltd.                      10:00-10:20 Presentation: ADC Site-Specific Conjugation Technology: Process Development and Control Strategies                      Speaker: Yu Zhang, Executive Director of ADC Chemistry &amp; CMC, DualityBio Ltd.                      10:20-10:40 Presentation: ADC process characterization and process validation                      10:40-11:00 Presentation: Key considerations for ADC clinical changes</p>	<p><b>Upstream Process Specialization</b>                      10:00-10:20 Presentation: Single-use Technology in Antibody Upstream Manufacturing: Considerations, Risks and Case Studies                      Speaker: He Li, Director, Sincere Pharmaceutical Group                      10:20-10:40 Presentation: Consideration and strategy for rapid bispecific antibody CMC development during IND stage                      Speaker: CMC Head of D3 Bio                      10:40-11:00 Presentation: Topic to be confirmed</p>
12:00-13:00	<p>12:00-13:00 Panel Discussion: ADC differentiation design strategy from early research and development                      Planner: Hu Li, VP, EIGHT ROADS                      Jiaqiang Cai, Cofounder &amp; CSO, MediLink Therapeutics                      Leo Liu, CSO, Inxmed                      Lei Fang, VP, CtM Bio                      Yuhong Zhou, Co-founder &amp; CSO, Bliss Biopharmaceutical (Hangzhou) .</p>	<p><b>ADC Process Topic</b>                      12:00-12:20 Presentation: Process-related                      Speaker: Qilu Pharmaceutical, Director of Manufacturing Process                      12:20-12:40 Presentation: ADC antibody molecular analysis method strategy and quality related                      Speaker: Lingrui Li, Deputy Director, Shanghai Miracogen .                      12:40-13:00 Presentation: Process-related                      Speaker: 美雅珂, 上游 Director of Manufacturing Process</p>	<p>12:00-13:00 Panel Discussion: Optimization and Innovation Practice of Biopharmaceutical Process Based on Commercial Value                      Speaker: Kaimeng Zhou, Vice President, Shanghai Hengrui Pharmaceutical                      Gang Xia, Science &amp; Strategy Officer, Zhejiang NovoCodex Biopharmaceuticals                      Yanfeng Zhang, Cofounder and President, AlaMab Therapeutics .                      Zhuobing Zhang, Executive Director, Deputy General Manager, Junshi Bioscience .</p>

# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>ADC Innovation and Development Technology Forum [R&amp;D]</b>	<b>ADC Innovation Forum [Process Quality]</b>	<b>Biopharmaceutical Innovation Process Development Technology Forum [Process]</b>
13:00-14:00	<p><b>Differentiation considerations from preclinical to clinical in ADC development</b>                      Planner: <a href="#">Stephen Xie, Senior Director, Clinical Development Clinical</a>                      13:00-13:20 Presentation: Topic to be confirmed                      Speaker: <a href="#">Peng Chen , Pr ipal Investigator of Preclinical Discovery, Antengene.</a>                      13:20-13:40 Presentation: Topic to be confirmed                      Speaker: <a href="#">Stephen Xie, Senior Director, Clinical Development Clinical</a>                      13:40-14:00 Presentation: Topic to be confirmed</p>	<p><b>ADC Quality Topic</b>                      13:00-13:20 Presentation: Quality research strategy for Antibody-drug Conjuate during clinical trials                      Speaker: <a href="#">Frank Fang, Director of Quality Department, Jiangsu Mabwell Health Pharmaceutical R&amp;D .</a>                      13:20-13:40 Presentation: Opportunity Available                      13:40-14:00 Presentation: Opportunity Available</p>	<p><b>Process Development</b>                      13:00-13:20 Presentation: Process-related                      Speaker: <a href="#">D3 Bio, CMC Director</a>                      13:20-13:40 Presentation: Opportunity Available                      13:40-14:00 Presentation: Opportunity Available</p>
15:00-16:00	<p><b>Pathological Research and Development of ADC Drugs</b>                      Planner: <a href="#">Hao Liu, Vice GM of Innovation &amp; R&amp;D Center, Qilu pharmaceutical</a>                      15:00-15:20 Presentation:                      Strategies for the elimination of B cells in immune system diseases                      Speaker: <a href="#">Hao Liu, Vice GM of Innovation &amp; R&amp;D Center, Qilu pharmaceutical</a>                      15:20-15:40 Presentation: Topic to be confirmed                      Speaker: <a href="#">Shi Liang, senior scientist, Qilu Pharmaceutical</a>                      15:40-16:00 Presentation: Topic to be confirmed</p>	<p>Technical Transfer Topic Under Planning</p>	<p>Exhibition time/BioPartnering</p>
16:00-17:00	<p><b>The frontier of ADC technology</b>                      Planner: <a href="#">Wei LIAN, Sr. Director of Translational Medicine, MediLink Therapeutics (Suzhou) .</a>                      16:00-16:20 Presentation: Development of Non-internalized ADC                      Speaker: <a href="#">Wei LIAN, Sr. Director of Translational Medicine, MediLink Therapeutics (Suzhou) .</a>                      16:20-16:40 Presentation: ADC R&amp;D                      Speaker: <a href="#">DeLiang Li, Senior Director Chemistry&amp;Bioprocess, LEPU BIOPHARMA</a>                      16:40-17:00 Presentation: Development progress of dual-payload ADC                      Speaker: <a href="#">Xianghai Cai, Vice President, Novatim Immune Therapeutics (Zhejiang) .</a></p>	<p>16:00-17:00 Panel Discussion: CMC Strategy of ADC Products from the Perspective of Commercial Production                      Speaker: <a href="#">Liang Xiao, Co-founder &amp; COO, MediLink Therapeutics</a>  <a href="#">Qing Huang, CTO, Biopharmaceutical (Hangzhou) .</a>  <a href="#">Charles Feng , Biologics CMC Executive Director , 3D Medicines .</a>  <a href="#">Shiwei Miao, Co-founder &amp; SVP, Hangzhou Sumgen Biotech .</a>  <a href="#">ImmuneOnco, Vice President of Process Management</a></p>	<p>Exhibition time/BioPartnering</p>

# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Biopharmaceutical Innovation Process Development Technology Forum [QA]</b>	<b>Biologics Innovation Forum [R&amp;D]</b>	<b>Other Biologics Innovation Forum [R&amp;D]</b>
09:00-10:00	Exhibition time/BioPartnering	<p><b>Preclinical development of bispecific TCE molecules</b>  Planner: Xuan Wu, Director of biology, Shanghai epimab  09:00-09:20 Presentation: Molecular design of dual antibody TCE  Speaker: EpimAb Biotherapeutics, Director of Antibody Engineering  09:20-09:40 Presentation: Development of dual antibody TCE candidate molecules  Speaker: EpimAb Biotherapeutics, Director of New Drug Discovery  09:40-10:00 Presentation: Preclinical safety evaluation of dual antibody TCE molecules  Speaker: EpimAb Biotherapeutics, Director of Preclinical Toxicology</p>	<p>09:00-09:20 Presentation: Development of Next-Generation Complement Inhibitor Drugs  Speaker: Lingnuo Pharmaceuticals, Founder  09:20-09:40 Presentation: Phase I/II Clinical Study of mTORC1/2 Inhibitor ATG-008 Combined with Toripalimab for the Treatment of Advanced Cervical Cancer  Speaker: Deqi Pharmaceuticals, Senior Director and Head of Clinical Translation  09:40-10:00 Presentation: Design, validation, and development of bispecific antibody for inflammatory bowel disease  Speaker: :Tao Chen, Head of New Drug Research Center, Chuangxin Biotech</p>
10:00-11:00	<p>10:00-11:00 Panel Discussion: International Quality Standards and Quality System Construction  Speaker: Ding Liu, currently Deputy General Manager, Qilu BioPharma  Cai Bao, Senior Vice President, Quality, Bio-Thera Solutions, Ltd.,  Xuejian Xu, CTO, Jiangsu Hengrui Pharmaceuticals  BeiGene, China Quality Director</p>	<p><b>TCE Autoimmunity</b>  Planner: Hua Ying, Vice president, Qilu pharmaceutical  10:00-10:20 Presentation: Thoughts on target selection for B-cell dominated autoimmune diseases and technology platforms  Speaker: Hao Liu, Vice GM of Innovation &amp; R&amp;D Center, Qilu pharmaceutical research institute  10:20-10:40  Presentation: Development and application of TCE for autoimmune diseases  Speaker: Qilu Pharmaceutical, R&amp;D Director  10:40-11:00 Presentation: Application of A Next-Gen Tri-specific T Cell Engager in Tumors and Autoimmune Diseases  Speaker: Yingfeng Huang, CEO, CytoCares</p>	<p>10:00-10:20 Presentation: Topic Confirmation  Speaker: Puzhong Discovery, Senior Director of R&amp;D  10:20-10:40 Presentation: Topic Confirmation  Speaker: Zhejiang Provincial Drug Inspection Center, Head of Biologics Inspection Group  10:40-11:00 Presentation: Topic Confirmation</p>
12:00-13:00	<p>12:00-12:20 Presentation: Quality-related  Speaker: Zhixiang, Deputy Director of Quality Control  12:20-12:40 Presentation: Quality-related  Speaker: Deputy Director of Quality Control, Suzhou ZaiChuang  12:40-13:00 Presentation: Quality-related  Speaker: China Resources Biomedical, Director of Analytical Development and QC Execution</p>	<p><b>Application of antibody site-specific conjugation technology in tumor and obesity therapy</b>  Planner: Deyong Song, Senior Director, Shandong boan biotechnology co ltd.  12:00-12:20 Presentation: Developing EGFR/B7H3 dual antibody ADC using novel sugar site coupling technology  Speaker: Deyong Song, Senior Director, Shandong boan biotechnology co ltd.  12:20-12:40 Presentation: Development of GIPR/GLP-1 antibody peptide conjugates using THIOMAB site directed coupling technology  Speaker: Chuangchuang Dong, Biologics Discovery Department, Shandong BoAn Biotechnology Co., Ltd.  12:40-13:00 Presentation: Exploration and research on innovative GD-</p>	Exhibition time/BioPartnering

# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<p><b>Biopharmaceutical Innovation Process Development Technology Forum [QA]</b></p>	<p><b>Biologics Innovation Forum [R&amp;D]</b></p>	
13:00-14:00	<p>13:00-13:20 Presentation: Quality-related  <a href="#">Speaker: BeiGene, Director of Quality Execution</a>            13:20-13:40 Presentation: Key points for quality research and control of ADC drugs  <a href="#">Speaker: Shantong Jiang, Assistant Manager, Shanghai Hengrui pharmaceuticals</a>            13:40-14:00 Presentation: Quality-related  <a href="#">Speaker: Le Wang, Clinical Operation, Clinical QC Director, Zai Lab</a></p>	<p>13:00-13:20 Presentation: Development of Autoimmune Drugs  <a href="#">Speaker: Sanofi Genzyme, Vice President of R&amp;D</a>            13:20-13:40 Presentation: R&amp;D Progress of Dual-Target T Cell Engager (TCE)  <a href="#">Speaker: Tianguo Biotech, Director &amp; Vice General Manager</a>            13:40-14:00 Presentation: Preclinical Development of T Cell Engager (TCE)  <a href="#">Speaker: Deqi Pharmaceuticals, Vice President</a></p>	Exhibition time/BioPartnering
15:00-16:00	<p>Biologics Technology Transfer Topic  <a href="#">Planner: Jiangsu Jiye Biotech, Quality Manager</a>            15:00-15:20 Presentation: Topic to be confirmed  <a href="#">Speaker: Jiangsu Jiye Biotech, Head of Biologics Technology Transfer</a>            15:20-15:40 Presentation: Topic to be confirmed  <a href="#">Speaker: Zhejiang Hangyu Pharmaceutical, Head of Technology Department</a>            15:40-16:00 Presentation: Topic to be confirmed  <a href="#">Speaker: Jiangsu Jiye Biotech, Quality Manager</a></p>	<p><b>Application of Antibody Conjugation Technology in Cancer and Obesity Treatment</b>  <a href="#">Planner: Boan Biotech, Senior Director, Biopharmaceutical Discovery Research</a>            15:00-15:20 Presentation: Development of EGFR/B7H3 Bispecific ADC Using Novel Glycan-Based Conjugation Technology  <a href="#">Speaker: Boan Biotech, Senior Director, Biopharmaceutical Discovery Research</a>            15:20-15:40 Presentation: Development of GIPR/GLP-1 Antibody-Peptide Conjugates Using THIOMAB Site-Specific Conjugation Technology  <a href="#">Speaker: Boan Biotech, Manager, Antibody Discovery Research</a>            15:40-16:00 Presentation: Exploratory Research on Innovative GD-2 Antibody-Drug Conjugates for Pediatric Cancer Treatment  <a href="#">Speaker: Boan Biotech, Manager</a></p>	Exhibition time/BioPartnering
16:00-17:00	<p>16:00-16:20 Presentation: Strategy of charge heterogeneity analysis and in-depth characterization of antibody  <a href="#">Speaker: Nana Kong, Director, CSPC Baike (Shandong) Biopharmaceutical</a> ,            16:20-16:40 Presentation: Analysis  <a href="#">Speaker: Simcere Bio-Pharmaceutical, Senior Director of Formulation Analysis</a>            16:40-17:00: Opportunities for Thematic Presentations            Now Open</p>	<p>16:00-17:00 Interview: Exploring More Innovative Drug Co-Development  <a href="#">Speakers: CSO, Xinlittai Pharmaceutical Senior President of R&amp;D, Zeyi Biotech Director of the Institute of Biomedicine, Nanjing ZHONGDA Tianqing Pharmaceutical</a></p>	Exhibition time/BioPartnering

# BI0CHINA 2025 Technology Forum

	March 13th	March 14th	March 15th
	Bioprocessing & Plants construction Management Forum [Production Management]	Nuclear Medicine Innovation Forum	Biopharmaceutical Production & Engineering Management Forum [Production Management]
09:00-10:00	Exhibition time/BioPartnering	<b>R&amp;D Focus on Radiopharmaceuticals</b> Planner: Ge Bai, Vice President of Sinotau, Chief Operating Officer of Glotope 09:00-09:20 Presentation: Global Advances and Analysis of Innovative Targets for Radiopharmaceuticals Speaker: Di Shen, Head of Innovation Acceleration, Sinotau Pharmaceutical Group 09:20-09:40 Presentation: Topic to be confirmed 09:40-10:00 Presentation: Topic to be confirmed	<b>International declaration and aseptic control</b> Planner: Rocky Bai, Quality VP, Suzhou Union Biopharm/Junshi Biosciences 09:00-09:20 Presentation: Topic to be confirmed 09:20-09:40 Presentation: Topic to be confirmed 09:40-10:00 Presentation: Topic to be confirmed
10:00-11:00	10:00-11:00 Panel Discussion: Commercial production reduces costs and reases efficiency Speaker: Xiaoming Yang, Chief Manufacturing Officer, RemeGen Haijun Wu, vp, Alphamab Lu Jiansheng, general manager, Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group	<b>R&amp;D Focus on Radiopharmaceuticals</b> Planner: C Ray Therapeutics 10:00-10:20 Presentation: Topic to be confirmed Speaker: C Ray Therapeutics, Vice President 10:20-10:40 Presentation: Topic to be confirmed 10:40-11:00 Presentation: Topic to be confirmed	10:00-11:00 Panel Discussion: Commercial production management and operation Speaker: Ding Liu, currently Deputy General Manager, Qilu BioPharma
12:00-13:00	12:00-12:20 Presentation: Life cycle management of antibody Drug substance process Speaker: Huaqiong Wang, DS Production director, Bio-Thera solutions Sterility Assurance and GMP Validation in Biopharmaceutical Manufacturing 12:20-12:40 Technology transfer and change strategy for drug substances of biological products 12:40-13:00 Presentation: Opportunity Available	12:00-13:00 Panel Discussion: Target selection and early clinical design of nuclear drugs Speaker: Xiaoxia.Zhang, VP, Smartnuclide Zheng Jim WANG, CEO/CSO, Theranosta Juan Zhang, SVP, Full Life Technologies	Production Operations Management Topic is Under Planning



# BI0CHINA 2025 Technology Forum

	March 13th	March 14th	March 15th
	Bioprocessing & Plants construction Management Forum [Production Management]	Nuclear Medicine Innovation Forum	Biopharmaceutical Production & Engineering Management Forum [Production Management]
13:00-14:00	<p>Process Control Across the Entire Lifecycle                      Planner: <a href="#">Salubris Pharmaceuticals, Vice President</a>                      13:00-13:20 Presentation: Considerations for scaling up the production process of antibody Drug substance                      Speaker: <a href="#">Wei Guo, Drug substance Manufacturing Manager, Salubris (suzhou) Pharmaceutical</a> .                      13:20-13:40 Presentation:                      Environmental Control Strategies for Shutdown of Biopharmaceutical Production Workshops                      Speaker: <a href="#">Salubris Pharmaceuticals, Deputy Manager, Formulations</a>                      13:40-14:00 Presentation: Topic to be confirmed</p>	<p>13:00-13:20 Presentation :                      Preclinical evaluation of a novel SSSTR2 targeting radioligand t herapy                      Speaker: <a href="#">Junyu Yang, Associate Director , Shanghai Full-Life Technologies</a>                      13:20-13:40 Presentation: Opportunity Available                      13:40-14:00 Presentation: Opportunity Available</p>	Exhibition time/BioPartnering
15:00-16:00	<p>Formulation Manufacturing                      15:00-15:20 Presentation: Topic to be confirmed                      Speaker: <a href="#">Alphamab Oncology, Formulation Production Manager</a></p>	<p>15:00-15:20 Presentation : Construction of R&amp;D Quality System                      Speaker: <a href="#">Andy Zhang, QA Assistant Director, BoomRay Pharmaceutical Co.,Ltd.</a>                      15:20-15:40 Presentation: Opportunity Available                      15:40-16:00 Presentation: Opportunity Available</p>	Exhibition time/BioPartnering
16:00-17:00	<p>16:00-17:00 Panel Discussion: Automated and Intelligent Factory Design                      Speaker: <a href="#">Hua Ni, VP, Mabwell (Shanghai) Bioscience</a></p>	A Special Session on Radiopharmaceutical Production Processes is under Planning	Exhibition time/BioPartnering



# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Biologics Innovation Development Technology Forum [Formulations]</b>	<b>Peptide Drug Innovation Forum</b>	<b>Peptide Drug Innovation Forum</b>
09:00-10:00	Exhibition time/BioPartnering	<p><b>Next-Generation GLP-1 Novel Drug R&amp;D</b>                      Planner: Weijun Shen, Institute Director, Shenzhen Bay Laboratory                      09:00-09:20 Presentation: Topic to be confirmed                      Speaker: Dou Liu, CEO, Shenzhen Oralead Pharma                      09:20-09:40 Presentation: Topic to be confirmed                      Speaker: Xiaoxin Chen, President, Guangdong Raynovent Biotechnology .                      09:40-10:00 Presentation: Topic to be confirmed                      Speaker: Yan Li, Director of Technology Development, Sciwind Biosciences</p>	<p><b>Innovation and delivery strategy of peptide preparations</b>                      Planner: V ent Qu,CTO, Shenzhen Sciencare Pharmaceutical                      09:00-09:20 Presentation:Peptide based Brain Targeted Drug Delivery Strategy                      Planner: V ent Qu,CTO, Shenzhen Sciencare Pharmaceutical                      09:20-09:40 Presentation:Peptides and their application in receptor-targeting drug delivery                      Speaker: Lichun Sun, Founder/President, Shenzhen Tyercan Bio-Pharma .                      09:40-10:00 Presentation:Development strategy for long-acting peptide preparations                      Speaker: Fei Yu, CEO, Novapath Pharma (Chengdu) .</p>
10:00-11:00	<p><b>Topic to be Confirmed</b>                      Speaker:Zhen Gu, Dean and Party Secretary of the School of Pharmaceutical Sciences, Zhejiang University, Director of the National Key Laboratory of Advanced Drug Delivery Systems</p>	<p><b>Next-Generation GLP-1 Novel Drug R&amp;D</b>                      Planner: Weijun Shen ,Institute Director ,Shenzhen Bay Laboratory                      10:00-10:20 Presentation: Topic to be confirmed                      Speaker : Chunlai Cao, CEO, The United Bio-Technology (Hengqin) CO.,Ltd                      10:20-11:00 Panel Discussion:GLP-1 Innovative Drug R&amp;D                      Moderator: Weijun Shen ,Institute Director ,Shenzhen Bay Laboratory                      Speaker : Dou Liu, CEO, Shenzhen Oralead Pharma                      Chunlai Cao, CEO, The United Bio-Technology (Hengqin) CO.,Ltd                      Xiaoxin Chen, President, Guangdong Raynovent Biotechnology .                      Yan Li, Director of Technology Development, Sciwind Biosciences</p>	<p><b>Molecular design and clinical development of innovative peptide drugs</b>                      10:00-10:20 Presentation:                      Screening peptides by mRNA display technology and its application in drug development                      Speaker: Yi Shi,Director,Shanghai Benemae Pharmaceutical                      10:20-10:40 Presentation: Long-Acting Growth Hormone CMC Development                      Speaker: Jing Zhu, CMC Senior Director, VISEN Pharmaceuticals                      10:40-11:00 Presentation: Opportunity Available</p>
12:00-13:00	<p>Planner: Dongmei Han,Shanghai Henlius Biotech .,Deputy General                      12:00-12:20 Presentation:Enhancing Product Market Competitiveness Through Formulation Design, Supporting Global Expansion                      Speaker: Holly Zhang,DPD Tech Transformation Associate Director,Henlius                      12:20-12:40 Presentation:Challenges and Case Studies in the Development of Hyaluronidase-Containing Co-Formulations 4o                      Speaker: Yuan Fang, Director of Product Development Department, Henlius                      12:40-13:00 Application and immunogenicity of hyaluronidase in subcutaneous formulation of biopharmaceuticals                      Speaker: HenliusBiotech,Director of Pharmacokinetics and Toxicology</p>	<p><b>Molecular Design and Clinical Development of GLP-1 Peptides</b>                      12:00-12:20 Presentation: Development of Hypoglycemic drugs and diet drugs around GLP-1 targets                      Speaker : Tongying Wang, Technical Director, hangzhou jiuyuan gene engineering co .,Ltd                      12:20-12:40 Presentation: GLP-1 Clinical Development                      Speaker :Huan Deng, Executive Medical Director, Innovent Biologics                      12:40-13:00 Presentation:Opportunity Available</p>	<p>12:00-13:00 Panel Discussion:Target selection and technological breakthroughs in peptide product development                      Speaker: An-bang LU,CEO,VISEN Pharmaceuticals                      Jiuyuan Gene Engineering,Vice President, Chief Engineer                      YuHeng Bio, Vice President of R&amp;D and Manufacturing; Anji Bio                      CSO</p>

# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Biologics Innovation Development Technology Forum [Formulations]</b>	<b>Peptide Drug Innovation Forum</b>	<b>Peptide Drug Innovation Forum</b>
13:00-14:00	<p>13:00-13:20 Presentation: Development of Subcutaneous Formulations for Antibody Drugs  <b>Speaker: Wu Yong, Associate Director, Bio-Thera Solutions, Ltd.</b></p> <p>13:20-13:40 Presentation: Formulation Focus  <b>Speaker: Ying Luo, Associate director, Lepu biopharma</b></p> <p>13:40-14:00 Presentation: Process and Formulation  <b>Speaker: Shangjian, Director of Downstream and Formulation Process Development</b></p>	<p><b>Development of new weight loss drugs</b>  <b>Planner: Chris Song, Deputy general manager &amp; Director of research, Shanghai Minwei Biotechnology Co.,LTD</b></p> <p>13:00-13:20 Presentation: Triple-G agonist effectively reduces ectopic adipose tissue  <b>Speaker : Chris Song, Deputy general manager &amp; Director of research, Shanghai Minwei Biotechnology Co.,LTD</b></p> <p>13:20-13:40 Presentation: Discovery and Clinical Validation of GLP-1/FGF21 Dual-Target New Drugs  <b>Speaker : Jiangyu Yan, Director, Sunshine Lake Pharma</b></p> <p>13:40-14:00 Presentation: Maximizing the Efficacy of Novel Drugs through Dosing Reduction  <b>Speaker: Minwei Biotechnology, Director of R&amp;D</b></p>	Exhibition time/BioPartnering
15:00-16:00	<b>Pharmaceutical Packaging &amp; Administration Forum</b>	<b>Research and industrialization of GLP-1 peptide drugs</b>	Exhibition time/BioPartnering
	Special Session on Biopharmaceutical Packaging and Regulations, in Planning...	<p><b>Planner: Livzon Group</b></p> <p>15:00-15:20 Presentation: Research and development strategies for biosynthetic polypeptide  <b>Speaker : Chen Qianqian, Vice General Manager of Project Management, Livzon Group</b></p> <p>15:20-15:40 Presentation: Production management of biosynthetic polypeptide drugs  <b>Speaker : Chang Liu, Executive Deputy General Manager, livzon</b></p> <p>15:40-16:00 Presentation: Peptide-Radionuclide Conjugate R&amp;D  <b>Speaker : Fa Liu, CSO , Full-Life Technologies</b></p> <p><b>PDC/peptide nuclide conjugate drug</b>  <b>Planner: Coherent Biopharma (Suzhou) .</b></p> <p>16:00-16:20 Presentation: Topic to be confirmed  <b>Speaker : Guitao Wang, VP, G.M. Assistant, VP of Research Institute, Coherent Biopharma</b></p> <p>16:20-16:40 Presentation: Topic to be confirmed  <b>Speaker : Mo Xu, CMO , Coherent Biopharma</b></p> <p>16:40-17:00 Presentation: Topic to be confirmed  <b>Speaker : JUN SHAO, CTO, Coherent Biopharma (Suzhou) .</b></p>	Exhibition time/BioPartnering
16:00-17:00	Special Session on Drug-Device Combinations, in Planning...		Exhibition time/BioPartnering





# BI0CHINA 2025 Technology Forum

Date	March 14th	March 15th
	Cell Therapy Innovation Forum [R&D]	Cell Therapy Innovation Forum [R&D]
09:00-10:00	<p>09:00-10:00 Panel Discussion: Innovative ideas for early research and development of cell therapy  <b>Speaker:</b> <a href="#">Yanyan Han, CSO, HRYZ Biotech Co</a>  <a href="#">Emily Tan, COO, Unixell Biotechnology</a>  <a href="#">Peter He, CSO, Orig ell Therapeutics</a>  <a href="#">Wen Limin, SVP, Simnova</a>  <a href="#">Lianjun Shen, SVP Head of R&amp;D, Gracell Biotechnologies</a></p>	<p><b>Early-Stage <math>\gamma\delta</math>T Research</b>  <b>Planner:</b> <a href="#">Min Wang, Vice President, PersonGen BioTherapeutics (Suzhou)</a> .            09:00-09:20 Presentation: Research on CMC process and Quality of <math>\gamma\delta</math>T cell therapy  <b>Speaker:</b> <a href="#">Min Wang, Vice President, PersonGen BioTherapeutics (Suzhou)</a> .            09:20-09:40            Presentation: illogeneic CAR gamma delta T: a novel strategy for the treatment of hematological and solid tumors  <b>Speaker:</b> <a href="#">Weiwei Ma, Co-founder/CTO, Unicet Biotech</a>            09:40-10:00 Presentation: The prospect and outlook of universal CAR - <math>\gamma\delta</math> T therapy for solid tumors  <b>Speaker:</b> <a href="#">Fengtao You, Director Innovative drug research Institute, PersonGen BioTherapeutics(Suzhou) Co.,Ltd.</a></p>
10:00-11:00	<p><b>Universal cell design and modification</b>  <b>Planner:</b> <a href="#">Bing Du, Professor of East China Normal University&amp; Co-founder of BRL Medicine</a>            10:00-10:20 Presentation: Application and clinical translation of gene editing in the development of universal CAR-T  <b>Speaker:</b> <a href="#">Speaker: Bing Du, Professor of East China Normal University&amp; Co-founder of BRL Medicine</a>            10:20-10:40 Presentation: Engineering allogeneic T cells with immunosuppressant-resistant transgenes for universal CAR-T therapy  <b>Speaker:</b> <a href="#">Xun Zeng, Research Fellow, Zhejiang university</a>            10:40-11:00 Presentation: Prospects and Considerations for Allogeneic CAR-T Cell Therapy Under the Dual Challenges of ADC and TCE  <b>Speaker:</b> <a href="#">Lin Yang, Founder, Chairman &amp; CEO, PersonGen BioTherapeutics (Suzhou)</a></p>	<p><b>Early-Stage Research on Cell Therapy for Solid Tumors</b>            10:00-10:20 Presentation: Early-Stage Research on Cell Therapy for Solid Tumors  <b>Speaker:</b> <a href="#">Frank Su, CEO, TCRCure Biopharma Ltd</a>            10:20-10:40 Presentation: Early-Stage DNT Research            10:40-11:00 Presentation: Early-Stage NKT Research</p> <p><b>Cell Therapy for Solid Tumor Innovative Therapies Special Session</b>            10:00-10:20 Presentation: Topic to Be Confirmed  <b>Speaker:</b> <a href="#">Tian Keya, Chief Technology Officer (CTO)</a>            10:20-10:40 Presentation: Early Research Directions for Universal TIL Therapy (Tentative)  <b>Speaker:</b> <a href="#">Xinghua Biotech, Founder &amp; Chief Scientific Officer (CSO)</a>            10:40-11:00 Presentation: Opportunity Available</p>
12:00-13:00	<p><b>Cell therapy in vivo editing</b>            12:00-12:20 Presentation: Application and clinical translation of in vivo gene editing therapy  <b>Speaker:</b> <a href="#">Bingbing Wu, Head of Portfolio Management, CorrectSequence Therapeutics</a>            12:20-12:40 Presentation: Topic to be confirmed  <b>Speaker:</b> <a href="#">Therorna</a>            12:40-13:00 Presentation: Opportunity Available</p>	<p>Early-Stage Research on CAR-T Therapy for Solid Tumors  <b>Speaker:</b> <a href="#">Peter He, CSO, Orig ell Therapeutics</a>            12:00-12:20 Presentation: Topic to be confirmed  <b>speaker:</b> <a href="#">Peter He, CSO, Orig ell Therapeutics</a>            12:20-12:40 Presentation: Topic to be confirmed  <b>Speaker:</b> <a href="#">Oricell Therapeutics, Vice President of Quality</a>            12:40-13:00 Presentation: Topic to be confirmed  <b>Speaker:</b> <a href="#">Oricell Therapeutics, Head of Process Development</a></p>

# BI0CHINA 2025 Technology Forum

Date	March 14th	March 15th
	Cell Therapy Innovation Forum [R&D]	Cell Therapy Innovation Forum [R&D]
13:00-14:00	<p><b>Early-Stage TCR-T Research</b>            Planner: <a href="#">XIANGXUE LIFE SCIENCES ,CSO</a>            13:00-13:20 Presentation: Topic to be confirmed            Speaker: <a href="#">XIANGXUE LIFE SCIENCES ,CSO</a>            13:20-13:40 Presentation: Topic to be confirmed            Speaker: <a href="#">YUSHENG OU,CMC director,Xlifesc</a>            13:40-14:00 Presentation: Topic to be confirmed</p>	<p><b>Cell Therapy Autoimmune Early Research Session</b>            13:00-13:20 Presentation: Topic to be confirmed            Speaker: <a href="#">VP, Xibiman Biotech</a>            13:20-13:40 Presentation: Topic to be confirmed            Speaker: <a href="#">Vice President of R&amp;D, Boyajiyin</a>            13:40-14:00 Presentation: Topic to be confirmed            Speaker: <a href="#">Founder, Chairman &amp; CEO, Ruishun Biotech</a></p>
15:00-16:00	<p><b>TIL Early Research</b>            Planner: <a href="#">Jingwei Sun, Director of R&amp;D, Grit Biotechnology</a>            15:00-15:20 Presentation: Breakthrough and development of TIL therapy in solid tumors            Speaker: <a href="#">Jingwei Sun, Director of R&amp;D, Grit Biotechnology</a>            15:20-15:40 Presentation: CMC development strategy for TIL products            Speaker: <a href="#">Alex Lei, CMC head, Grit Biotech</a>            15:40-16:00 Presentation: Opportunity Available</p>	Exhibition time/BioPartnering
16:00-17:00	<p><b>CAR-NK Early Research</b>            Planner: <a href="#">Shuang Mei,CTO, Imbioray (Hangzhou) Biomedicine</a>            16:00-16:20 Presentation: The application of conjugated-antibody redirected ready-to-use allogeneic NK cell in solid tumor therapy            Speaker: <a href="#">Wang Cong, R&amp;D director, IMBIORAY (Hangzhou) Biomedicine</a>            16:20-16:40Presentation: The application of conjugated-antibody redirected ready-to-use allogeneic NK cell in leukemia therapy            Speaker: <a href="#">Miao Junchao, R&amp;D Senior manager,IMBIORAY (Hangzhou) Biomedicine</a>            16:40-17:00 Presentation: Clinical Application of ready-to-use allogeneic NK cell products against non-tumor indications            Speaker: <a href="#">Shuang Mei,CTO, Imbioray (Hangzhou) Biomedicine</a></p>	Exhibition time/BioPartnering

# BIOCHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	Cell Therapy Innovation Forum [Process and Quality Manufacturing]	Cell Therapy Innovation Forum [Process and Quality Manufacturing]	Gene Therapy Innovation Forum
09:00-10:00	Exhibition time/BioPartnering	<p><b>TIL Product Process Development and Quality Control</b>            09:00-09:20 Presentation: Topic to be confirmed  <b>Speaker:</b> Huajun Jin, Founder, CEO &amp; CTO, Shanghai Juncell Therapeutics .</p> <p>09:20-09:40 Presentation: Topic to be confirmed  <b>Speaker:</b> Huasai Berman Holdings,CTO</p> <p>09:40-10:00 Presentation:Opportunity Available</p>	<p>09:00-10:00 Panel Discussion:The development and optimization direction of gene therapy  <b>Speaker:</b> Wei Guo, CSO, SineuGene            Yixiong Chen, CSO, Lingyi Biotech            Robin Tan, Cofounder/CTO, Refreshgene Therapeutics</p>
10:00-11:00	Exhibition time/BioPartnering	<p><b>Stem cell therapy - the path to BLA</b>  <b>Planner:</b> Jing Fan, Founder &amp; CEO, Hopstem Biotechnology</p> <p>12:00-12:20 Presentation: Potency marker and assay development  <b>Speaker:</b> Anxin Wang, Senior scientist, Hopstem Bioengineering LLC</p> <p>12:20-12:40 Presentation: The PK/PD challenges in stem cell non-clinic and clinic study  <b>Speaker:</b> Jing Fan, Founder &amp; CEO, Hopstem Biotechnology</p> <p>12:40-13:00 Presentation: Considerations on Clinical Designs and Endpoint Settings of Different Cell Therapy Products  <b>Speaker:</b> Shuning Zhang,Vice President,Zhejiang Hopstem</p>	<p><b>Innovative drug development for gene therapy targeting major diseases</b>  <b>Planner:</b> Chang TAN,VP,Ugene-X Biotech .,</p> <p>12:00-12:20 Presentation:Optogenetic Gene Therapy for Photoreceptor Degenerative Diseases  <b>Speaker:</b> Chang TAN,VP,Ugene-X Biotech .,</p> <p>12:20-12:40 Presentation:Complement Regulation Gene Therapy for Dry Age-Related Macular Degeneration  <b>Speaker:</b> UgeneX Therapeutics,Vice President of R&amp;D</p> <p>12:40-13:00 Presentation:Neurotransdifferentiation Gene Therapy for Retinal Ganglion Cell Degenerative Diseases  <b>Speaker:</b> UgeneX Therapeutics,Senior Director of R&amp;D</p>
12:00-13:00	<p><b>CART Commercialization Capacity Design</b>  <b>Planner:</b> Sheng Wang, NJ Site GM, Nanjing IASO Biotechnology</p> <p>12:00-12:20 Presentation: Topic to be confirmed  <b>Speaker:</b> Sheng Wang, NJ Site GM, Nanjing IASO Biotechnology</p> <p>12:20-13:00 Panel Discussion:Topic to be confirmed  <b>Moderator:</b> Sheng Wang, NJ Site GM, Nanjing IASO Biotechnology  <b>Speaker:</b> Ivan Lin, MAH Manufacturing Responsible Person, JW Therapeutics (Shanghai)            Peng Yuzhong,Manufacturing VP,Juventas            Ruina Shi, VP, Beijing Immunopharm Technology .</p>	<p><b>Quality control of materials used in the production of cell therapy products</b>  <b>Planner:</b> Qi Feifei, Cofounder &amp; CTO, Immunopharm Technology .</p> <p>12:00-12:20 Presentation:Quality control of starting materials for the production of cell therapy products</p> <p>12:20-12:40 Presentation:Quality control of other raw materials and excipients used in the production of cell therapy products</p> <p>12:40-13:00 Presentation:Research on Quality Control and Compatibility of Disposable Consumables and Packaging Materials for Cell Therapy Product Production</p>	<p><b>Expanding the indications for AAV gene therapy through the development of innovative vectors</b>  <b>Planner:</b> Lei Zhao, Executive Director, Cure Genetics .</p> <p>10:00-10:20 Presentation:Introduction and Comparison of Advantages and Disadvantages of Innovative AAV Vector Development Platforms  <b>Speaker:</b> Lei Zhao, Executive Director, Cure Genetics .</p> <p>10:20-10:40 Presentation:Key Technologies in Directed Evolution for Developing Tissue-Specific AAV Vectors  <b>Speaker:</b> Tongxin.Liu, Associated Director,Curegenetics</p> <p>10:40-11:00 Development of AAV Vectors Targeting Tumors and Their Applications in Cancer Immunotherapy  <b>Speaker:</b> yongji Jiang, Associate Director,Curegenetics</p>

# BIOCHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Cell Therapy Innovation Forum [Process and Quality Manufacturing]</b>	<b>Cell Therapy Innovation Forum [Process and Quality Manufacturing]</b>	<b>Gene Therapy Innovation Forum</b>
<b>13:00-14:00</b>	<p><b>CAR-T quality control from IND to BLA</b>                      Planner: <a href="#">Mingyang Gu, GM Assistant, Nanjing AcrolImmune Biopharmaceutical. Ltd.</a>                      13:00-13:20 Presentation: Quality control strategies for CAR-T product BLA submission                      Speaker: <a href="#">Mingyang Gu, GM Assistant, Nanjing AcrolImmune Biopharmaceutical. Ltd.</a>                      13:20-13:40 Presentation: Development and Quality Control of Cell Therapy Products                      Speaker: <a href="#">Richard Yuan, Head of Quality, Neukio Biotherapeutics</a>                      13:40-14:00 Presentation: Topic to be confirmed                      Speaker: <a href="#">Nuwacell, Quality Director</a></p>	<p>13:00-14:00 Panel Discussion: Full life cycle management of materials used in the production of cell therapy products                      Planner: <a href="#">Qi Feifei, Cofounder &amp; CTO, Immunopharm Technology</a>                      Speaker: <a href="#">Oricell Therapeutics, Vice President of Quality</a></p>	<p><b>Gene Therapy Innovation Drug Development</b>                      13:00-13:20 Presentation: Topic Confirmation                      Speaker: <a href="#">Shenxi Fusheng, Co-CEO</a>                      13:20-13:40 Presentation: Clinical Development Strategies and Challenges of Gene Therapy Products                      Speaker: <a href="#">Zhengxu Bio, Head of Resource Management</a>                      13:40-14:00 Presentation:                      Oncolytic virus: what is the way out of drug development?                      Speaker: <a href="#">Grace Zhou, ImmVira, CEO</a></p>



# BIOCHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Cell Therapy Innovation Forum [Process and Quality Manufacturing]</b>	<b>Cell Therapy Innovation Forum [Process and Quality Manufacturing]</b>	<b>Gene Therapy Innovation Forum</b>
15:00-16:00	15:00-16:00 Panel Discussion:Change and Quality Management Speaker: James Wang,CTO, Juventas Cell Therapy Ltd. Speaker: Oricell Therapeutics,Senior Vice President (Quality) Speaker: Wang Lin,Manufacturing Center General Manager,Hebei Senlang Biotechnology	15:00-16:00 Panel Discussion:Cell therapy intelligent manufacturing - equipment and facility automation Speaker: Mingchun Wei, VP of Manufacturing,FOSUNKite Peng Yuzhong,Manufacturing VP,Juventas	Exhibition time/BioPartnering
16:00-17:00	Panel Discussion:Cell therapy intelligent manufacturing - equipment and facility automation Speaker: Mingchun Wei, VP of Manufacturing,FOSUNKite Peng Yuzhong,Manufacturing VP,Juventas	<b>Quality and Production of Gene Therapy</b> 15:00-15:20 Presentation: Production process and quality control strategy of rAAV gene therapy drugs Speaker: Herman He, CMC Head, SineuGene Therapeutics 15:20-15:40 Presentation:Basis for Establishing Quality Standards for Gene and Cell Therapy Products (Registration Application) Speaker: Zhuxu Dong, Quality Director, Kanglin Biotec 15:40-16:00 Presentation:Research on Active Methods in Gene Therapy Speaker: Jun Xiao,Quality VP,Shanghai Vitalgen BioPharma 16:00-16:20 Presentation:Next-Generation Sequencing (NGS) Analysis of AAV Gene Therapy Products Example Speaker: Fangtuo Biotechnology ,Quality Manager 16:20-17:00 Panel Discussion: Production direction of gene therapy technology Speaker: Vitalgen,Quality VP	Exhibition time/BioPartnering

# BIOCHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Small RNA Therapeutics Innovation Forum</b>	<b>mRNA Innovation Forum</b>	<b>Nucleic acid drug innovation and development forum</b>
09:00-10:00	Exhibition time/BioPartnering	<p><b>Chemical delivery</b>                      Planner: <a href="#">Xinpeng Ma, VP, Abogen Biosciences</a>                      09:00-09:20 Presentation:                      The Development History of mRNA Delivery Systems and recent Research progress in Abogen                      Speaker: <a href="#">Xinpeng Ma, VP, Abogen Biosciences</a>                      09:20-09:40 Presentation: Research progress on mRNA delivery systems                      Speaker: <a href="#">Jianbin Tang, Professor, Zhejiang University</a>                      09:40-10:00 Presentation: Development of mRNA in situ delivery systems                      Speaker: <a href="#">Jiaqi Lin, Founder &amp; Chairman, Shenzhen Proxybio Biotechnology</a></p>	<b>Innovative drug delivery technology development topic, in planning...</b>
10:00-11:00	Exhibition time/BioPartnering	<p><b>From early research to CMC</b>                      Planner: <a href="#">Changyun Xiong, CEO, Ningbo Vigor Biologics</a>                      10:00-10:20 Presentation:                      Optimization and Application of Self replicating mRNA System                      Speaker: <a href="#">Wang Youru, CSO, Ningbo Junjian Biotechnology</a> .                      10:20-10:40 Presentation :                      CHAMP targeted protein degradation platform- ERK5 degrader                      Speaker: <a href="#">Changyun Xiong, CEO, Ningbo Vigor Biologics</a>                      10:40-11:00                      Presentation:Quality system for self replicating mRNA vaccines                      Speaker: <a href="#">Zhi Li, Director, Ningbo Junjian Biotechnology</a></p>	<p><b>Circular RNA process topic</b>                      Planner: <a href="#">Jingyuan Wu, CMC Director, Shanghai CirCode Biomed</a>                      13:00-13:20 Presentation:CMC Considerations for Circular RNA                      Speaker: <a href="#">Jingyuan Wu, CMC Director, Shanghai CirCode Biomed</a>                      13:20-13:40 Presentation:Non-clinical Progress of Circular RNA                      13:40-14:00 Presentation:Clinical Applications of Circular RNA</p>
12:00-13:00	<p><b>Molecular design and delivery</b>                      12:00-12:20 Presentation:Novel Lipid Nanoparticle-Based Nucleic Acid Delivery System                      Speaker: <a href="#">Robert J. Lee, CSO, Zhejiang Haichang Biotech</a> .                      12:20-12:40 Presentation:Application of Small Nucleic Acid Drugs in Cancer Treatment                      Speaker: <a href="#">Bai Jun/Senior Scientist//Zhejiang Haichang Biotechnology</a> .  <b>Preclinical research and development</b>                      Planner: <a href="#">Jianwu Fang, SVP, Rona Therapeutics</a>                      12:40-13:00 Presentation: Topic to be confirmed                      Speaker: <a href="#">Leaderna Therapeutic,CEO</a></p>	<p><b>CMC Development Overview</b>                      Planner: <a href="#">Shengnan Xiang, VP, Starna Therapeutics</a>                      12:00-12:20                      Presentation:Application of targeted delivery LNP technology in mRNA vaccines and analysis of CMC key points                      Speaker: <a href="#">Shengnan Xiang, VP, Starna Therapeutics</a>                      12:20-12:40 Presentation: Topic to be confirmed                      12:40-13:00 Presentation: Quality Control for Circular RNA                      Speaker: <a href="#">Therorna</a> .</p>	<p>Antibody-Nucleic Acid Conjugates and Extrhepatic Delivery of Nucleic Acid Drugs                      Planner: <a href="#">WEI ZHANG, VP, LINNO PHARMACEUTICALS</a>                      10:00-10:20 Presentation:Nanobody-Mediated Blood-Brain Barrier Drug Delivery and Its Application in CNS-Targeted Small Nucleic Acid Drug Development                      Speaker: <a href="#">Leading Innovation,Vice President of R&amp;D</a>                      10:20-10:40 Presentation: Topic to be confirmed                      10:40-11:00 Presentation: Topic to be confirmed</p>

# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Small RNA Therapeutics Innovation Forum</b>	<b>mRNA Innovation Forum</b>	<b>Innovative Nucleic Acid Drug Development Forum</b>
13:00-14:00	<p>13:00-13:20 Presentation: Topic to be confirmed  <b>Speaker: Runjia Biological ,Vice President of Biotechnology</b></p> <p>13:20-14:00 Panel Discussion:Progress and Future Trends in the Development of Small Nucleic Acid Drugs</p>	<p>13:00-13:20 Presentation: Topic to be confirmed  <b>Speaker: Aibo Biotechnology,Director of Formulation Development</b></p> <p>13:20-13:40 Presentation: Topic to be confirmed  <b>Speaker: Youjia (Hangzhou) Biomedical Technology,Formulation Director</b></p> <p>13:40-14:00 Presentation: Opportunity Available</p>	<p>13:00-14:00 Panel Discussion: Registration and clinical development of nucleic acid drugs  <b>Speaker:Jing Fu,VP,Suzhou Ribo Lifescience SHANGHAI RNACURE BIOPHARMA Regulatory Affairs vp</b></p>
15:00-16:00	<p><b>Clinical development</b>  <b>Planner : Andrea Wen, Medical Director , Visirna Therapeutics</b></p> <p>15:00-15:20 Presentation: Insights on the development strategy of siRNA drug for the treatment of chronic diseases  <b>Speaker : Chloe YOU,Clinical Development EVP,Visirna Therapeutics</b></p> <p>15:20-15:40 Presentation: Clinical development strategies for siRNA drug in cardiovascular and metabolism diseases  <b>Speaker: Qi Lihang,Medical Director,VISIRNA</b></p> <p>15:40-16:00 Presentation: Clinical development strategies for siRNA drug in liver diseases  <b>Speaker: Qi Lihang,Medical Director,VISIRNA</b></p>	<p><b>mRNA Drug Development Forum</b></p> <p>15:00-15:20 Presentation: Topic to be confirmed  <b>Speaker: Fisher Yu,VP,Starna Therapeutics</b></p> <p>15:20-15:40 Presentation:mRNA Drug Development Forum  <b>Speaker: CSPC,Director of Nucleic Acid Drug Research Institute</b></p> <p>15:40-16:00 Presentation: Topic to be confirmed  <b>Speaker: Lulu Fu,Director of Formulation Development ,Youjia (Hangzhou) Biomedical Technology CO., LTD</b></p>	Exhibition time/BioPartnering
16:00-17:00	<p><b>CMC Development Forum</b>  <b>Planner: LiQing, Director of Oligonucleotides, Junshi Bioscience .</b></p> <p>16:00-16:20 Presentation: Application of Chemical Modifications and Ligands to Oligo-Based Drugs and Thereof CMC Development  <b>Speaker: LiQing, Director of Oligonucleotides, Junshi Bioscience .</b></p> <p>16:20-16:40 Presentation: Nonclinical pharmacological and toxicological issues of small interfering RNAs  <b>Speaker: Min Hong, Director of Pharmacology and Toxicology,Junshi Biosciences</b></p> <p>16:40-17:00 Presentation: Topic to be confirmed  <b>Speaker: Lorenzo Xie, CSO &amp; IP VP, Ractigen Therapeutics</b></p>	Opportunities for Thematic Presentations Now Open	Exhibition time/BioPartnering



# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	Small Molecule Drug Innovation Forum	Small Molecule Drug Innovation Forum	Small Molecule Drug Innovation Forum
09:00-10:00	Exhibition time/BioPartnering	09:00-10:00 Panel Discussion: Innovative small molecule drug development based on potential targets and technology platforms Speaker: Guiping Zhang, Co-Founder /VP, Suzhou Genhouse Bio Co., Ltd Lily Zou, Co-Founder and CEO, Degron Therapeutics Yingxiang Wang, Chairman&CEO, Jacobio Pharma Zhang Ling, CMO, InventisBio TYK Medicines, CSO Simcere Pharmaceutical ,vp	09:00-10:00 Panel Discussion: Development ideas for non tumor indications Speaker: Jiahong Zhao, CMO, CGeneTech Xu Ruo, VP , Kintor pharmaceuticals Jane Wang, CSO, Salubris Pharmaceuticals Yi Zhou, CSO, Phaeno Therapeutics Co., Ltd. Arkbiosciences, VP
10:00-11:00	<b>Development and Transfer of Quality Control Methods for Small Molecule Drugs</b> Planner: Innocare Pharma , Vice President 10:00-10:20 <b>Presentation: CMC Registration Requirement at Different Development Stage</b> Speaker: Ming Zhang, Director of pharmaceutical analysis, Beijing Innocare 10:20-10:40 <b>Presentation: General consideration for the impurity study in small molecule APIs and Quality control Strategies for ASD p reparations</b> Speaker: Innocare Pharma , Director of Analytics 10:40-11:00 Key Points in Analytical Method Transfer Speaker: Jason Sun, Director of Quality Management, Beijing Innocare	<b>PROTAC</b> Planner: Ranok Therapeutics(Hangzhou)Co.Ltd. 10:00-10:20 Presentation: A new strategy for targeting KRAS degradation agents Speaker: Chenghao Ying, Director of Medicinal Chemistry, Ranok Therapeutics(Hangzhou)Co.Ltd. 10:20-10:40 Presentation: CHAMP Egg Self Degradation Platform and ERK5 Degradation Agent Speaker: Ele Yang, scientist, Ranok Therapeutics(Hangzhou)Co.Ltd.	<b>Early research and clinical development of drugs for metabolic diseases</b> Planner: CGeneTech 10:00-10:20 <b>Application of pharmacometrics in new drug development</b> Speaker: Jinmiao Lu, Director, CGeneTech (Suzhou, China) . 10:20-10:40 Presentation: Development of DPP-4 inhibitor - Sentaglipitin Speaker: Zhenwu Ouyang, Director of Medicinal Chemistry, CGeneTech 10:40-11:00 Presentation: The efficacy and safety of sentaglipitin Speaker: Jinmiao Lu, Director, CGeneTech (Suzhou, China) .
12:00-13:00	<b>Tumor drug CMC</b> Planner: Yong-Guo Li, Chairman and CSO), JOYO Pharma 12:00-12:20 Presentation: Topic to be confirmed Speaker: Yong-Guo Li, Chairman and CSO), JOYO Pharma 12:20-12:40 Presentation: Topic to be confirmed Speaker: Lei Li, Senior Director, Guangzhou JOYO Pharma 12:40-13:00 Presentation: Topic to be confirmed Speaker: Jianming Dong, Senior Director of Pharmacy, Guangzhou JOYO	<b>Preclinical and Clinical Exploration of Oncology Drug Development</b> Planner: Yu Xiaohong, Vice President of Global R&D Center, Fosun Pharma; Chairman of Jiangsu Xing Sheng Xin Hui Pharmaceutical . 12:00-12:20 Presentation: Fosun Pharma's layout strategy in the field of oncology Speaker: Xiang Li, CSO, Innovative Medicines , Fosun Pharma 12:20-12:40 Presentation: Preclinical Exploration of Combination Therapy with New Small Mole Oncology Drugs Speaker: Yu Xiaohong, Vice President of Global R&D Center, Fosun Pharma; Chairman of Jiangsu Xing Sheng Xin Hui Pharmaceutical . 12:40-13:00 Presentation: Consideration of clinical development strategies for small molecule new drugs for tumors Speaker: Julia Wu, CMO(oncology), Fosunpharma Global R&D center	<b>Challenge the development of unapproachable targets - KRAS inhibitors</b> 12:00-12:20 Presentation: Development of a new generation of BTK inhibitors Speaker: Yingfu Li, CEO, Founder, Chengdu Hyperway Pharmaceuticals Co., Ltd. 12:20-12:40 Presentation: Topic to be confirmed Speaker: Casey Zhuo, Senior director, Chengdu Hyperway Pharmaceuticals



# BIOCHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	Small Molecule Drug Innovation Forum	Small Molecule Drug Innovation Forum	Small Molecule Drug Innovation Forum
13:00-14:00	<p><b>Tumor drug quality design: chemical drug synthesis process, parameter determination and analysis methods</b>                      Planner: Lushan Zhou, Senior Principal Investigator, BeiGene                      13:00-13:20 Presentation: The application of DoE in small molecule drug substance late-phase process development                      Speaker: Qun Jiang, CMC DS AD, BeiGene Ltd.                      13:20-13:40 Presentation: Development of Stability-indicating HPLC Methods for Small Molecules using AQbD                      Speaker: Lushan Zhou, Senior Principal Investigator, BeiGene</p>	<p><b>Oncology drug R&amp;D</b>                      13:00-13:20 Presentation: Baiyu's Small Molecule Innovation and R&amp;D Case Sharing                      Speaker: Sichuan Yuzhi Pharmaceutical                      13:20-13:40 Presentation: Strategies for Early-Stage API Process Development and Global Success Stories                      Speaker: Yangyin Xie, CMC Associate Director, Allorion                      13:40-14:00 Presentation: Early Clinical Development Strategies for Small Molecule Innovative Drugs                      Speaker: Jacobio, Senior Clinical Director</p>	<p>13:00-13:20 Presentation: <b>Autoimmune disease drug R&amp;D</b>                      Speaker: Roger Liu, Executive Director of Clinical Medicine, LYNK PHARMACEUTICALS                      13:20-13:40 Presentation: Research and development of anti-infective drugs                      Speaker: Yi Zhou, CSO, Phaeno Therapeutics Co., Ltd.                      13:40-14:00 Presentation: Opportunity Available</p>
15:00-16:00	<p>15:00-16:00 Panel Discussion: CMC Strategy for Global Development of Innovative Small Molecule Drugs                      Speaker: Yangyin Xie, CMC Associate Director, Allorion                      Jingrong Li, CTO, Genfleet                      Yongguo Li, Chairman and CSO, JOYO Pharma                      Qilu Ruige Pharmaceutical, CTO</p>	<p>15:00-16:00 Panel Discussion: Multi therapy development for CNS diseases                      Planner: Xianbo Zhou, CEO, AstraNeura                      Speaker: Xiaoming Guan, President, 4B Technologies                      Yingfu Li, CEO, Founder, Chengdu Hyperway Pharmaceuticals                      Sansheng, CEO</p>	Exhibition time/BioPartnering
16:00-17:00	<p><b>A Brief Discussion on the Key Points of Improving New Drug CMC Research</b>                      Planner: Xiaojun Zhang, Director of the Institute for Pharmaceuticals, Beijing R&amp;D center, CSPC Pharmaceutical Group Limited                      16:00-16:20 Presentation: Research progress on long-acting delivery technology of small molecules                      Speaker: Xiaojun Zhang, Director of the Institute for Pharmaceuticals, Beijing R&amp;D center, CSPC Pharmaceutical Group Limited                      16:20-16:40 Presentation: Key Points of Prescription and Process Design for New Long-acting Formulation                      Speaker: Liang Xue, Sr Formulation Scientist, CSPC Pharmaceutical Group                      16:40-17:00 Presentation: Quality Control of Drug Formulations                      Speaker: Meng Xiangyan, Senior Analyst, CSPC</p>	<p>16:00-17:00 Panel Discussion: CNS drug clinical practice                      Planner: Zhihong Lu, Clinical Development/CMO, Shanghai Zhimeng Biopharma,                      Speaker: Lan Ge, CMO, Tenacia Biotechnology (Shanghai)                      Takeda, Vice President of APAC Development Center and Head of Clinical Development</p>	Exhibition time/BioPartnering



# BI0CHINA 2025 Technology Forum

Date	March 13th	March 14th	March 15th
	<b>Biopharmaceutical Industry Supply Chain</b>	<b>Discussion on the construction and application needs of university laboratories.</b>	<b>University Laboratory Construction and Operations Management</b>
09:00-10:00	Exhibition time/BioPartnering	Exhibition time/BioPartnering	09:00-09:20 Presentation: Topic to be confirmed Speaker: <a href="#">Soochow University, Director of Laboratory and Equipment Management</a> 09:20-09:40 Presentation: Topic to be confirmed Speaker: <a href="#">Nanjing Medical University, Director of the Analytical Testing Center</a> 09:40-10:00 Presentation: Topic to be confirmed Speaker: <a href="#">Jie Xu, Director of Instrument Platform, The School of Life Sciences and Biotechnology (SLSB) of Shanghai Jiao Tong University (SJTU)</a>
10:00-11:00	Exhibition time/BioPartnering	Exhibition time/BioPartnering	10:00-10:20 Presentation: Establishment of a lifeomics technology-based shared facility as an enabler for innovative biomedical and biopharmaceutical development Speaker: <a href="#">MU WANG, Xi'an Jiaotong-Liverpool University</a> 10:20-10:40 Presentation: Instrument sharing platform construction and equipment application exchange Speaker: <a href="#">Shi Li, vice director of science and technology development, Guangzhou Laboratory</a> 10:40-11:00 Presentation: Topic to be confirmed
12:00-13:00	12:00-12:20 Presentation: Integration of Biomedical Procurement Supply Chain: Strategic Practice of Collaborative Cost Reduction and Efficiency Enhancement 12:20-12:40 Presentation: Optimization of biopharmaceutical procurement supply chain from a global perspective	Instrument Development Seminar	Exhibition time/BioPartnering
13:00-14:00	13:00-14:00 Panel Discussion: Collection of Cases on Digital Transformation of Biopharmaceutical Procurement Supply Chain	Reagents and Consumables Seminar	Exhibition time/BioPartnering
15:00-16:00	[Supply Chain Brainstorming] 15:00-15:20 Presentation: Standardized procurement processes and case sharing 15:20-16:00 Panel Discussion: Negotiation skills with top suppliers to strengthen customer relationships	<b>【Brainstorming】</b>	Exhibition time/BioPartnering
16:00-17:00	[Supply Chain Brainstorming] 16:00-16:20 Presentation: Building a supply chain system for growing companies 16:20-17:00 Panel Discussion: Building a supply chain from 0 to 1 to drive innovative drug development business growth	<b>【Brainstorming】</b>	Exhibition time/BioPartnering

# BIOCHINA 2025 Brainstorming

Date	March 13th	March 14th	March 15th
	<b>[Brainstorming] Regulatory submission management / Supply chain management.</b>	<b>[Brainstorming] Innovation Development - Formulations / Instruments &amp; Equipment / Raw Materials / Peptides.</b>	<b>[Brainstorming] New drug development strategies for different indications</b>
09:00-10:00	Exhibition time/BioPartnering	09:00-10:00Development of new formulations	09:00-10:00Panel Discussion:Multi therapy development for autoimmune diseases <a href="#">Speaker: Meng Qiao, Director, Pfizer (China) Research and Development</a> .
10:00-11:00	Exhibition time/BioPartnering	10:00-11:00Development of new formulations	10:00-11:00 Panel Discussion:Multi therapy development for ophthalmic drugs
12:00-13:00	12:00-12:20Presentation:Biologics product lifecycle registration management <a href="#">Speaker: Audrey Xu, Director of DSDC and RA, 3DMed</a> 12:20-13:00Panel Discussion:Experience sharing in registration and application <a href="#">Speaker: Rebecca Zhang, SVP, CANbridge PharmaHuilan Ou,SVP,Dragonboat Biopharmaceutical</a> <a href="#">Audrey Xu, Director of DSDC and RA, 3DMed</a> <a href="#">DualityBio,Vice President of Drug Registration</a>	12:00-13:00Exploration into the Development Requirements of Instruments and Equipment in University Laboratories	12:00-13:00 Panel Discussion:Multi therapy development for metabolic drugs
13:00-14:00	13:00-14:00Panel Discussion:Experience sharing of innovative product registration and application <a href="#">Speaker: Hao WANG,RA SD,Kanglin Biotech</a> <a href="#">Shuping Fang,director,Simcere</a> <a href="#">Junshi Biosciences,Senior Director</a> <a href="#">Oricell Therapeutics,Senior Director of Regulatory Affairs</a>	13:00-14:00Exploration into the Development Requirements of Instruments and Equipment in University Laboratories	Exhibition time/BioPartnering
15:00-16:00	15:00-16:00Supply chain management: Procurement and negotiation skills	15:00-16:00Innovative design of peptides	Exhibition time/BioPartnering
16:00-17:00	16:00-17:00Supply chain management: From 0 to 1	16:00-17:00Innovative design of peptides	Exhibition time/BioPartnering



# BIOCHINA 2025 Brainstorming

Date	March 13th	March 14th	March 15th
	<b>[Brainstorming] Early R&amp;D Innovation - Cell Therapy / PROTAC / Targets</b>	<b>[Brainstorming] Biologic Drug Process / Quality / Production</b>	<b>[Brainstorming] Early R&amp;D Innovation - Bispecific Antibodies / Nucleic Acids / ADCs</b>
09:00-10:00	Exhibition time/BioPartnering	09:00-10:00 Panel Discussion: Small molecule mass analysis Speaker: Yang Gao, Senior Director, Analytical R&D, BeiGene Nociron Biopharma, Director of Analytical	09:00-10:00 Dual antibody research and development
10:00-11:00	Exhibition time/BioPartnering	10:00-11:00 Panel Discussion: Small molecule mass analysis	10:00-11:00 Nucleic acid delivery
12:00-13:00	12:00-13:00 Panel Discussion: Early research on cell therapy Speaker: Bo Pei, VP, BIOHENG Li Si, CTO, TCR Cure Biopharma Ltd Xie Jiajia, CTO, GeneyCell GU HAIHUA, Sr Director, JW Theapeutics	12:00-13:00 Panel Discussion: Development of gene therapy technology Speaker: Min Zhang, VP, Neurophth	12:00-13:00 Panel Discussion: Preclinical evaluation of ADC drugs
13:00-14:00	13:00-14:00 Panel Discussion: Preclinical evaluation of cell therapy Speaker: Wenjie Yin, Senior Director, Research & Development, A member of the AstraZeneca Group Lemon Biotech, Executive Director	13:00-14:00 Panel Discussion: Development of gene therapy technology Speaker: Min Zhang, VP, Neurophth	Exhibition time/BioPartnering
15:00-16:00	15:00-16:00 Panel Discussion: PROTAC New Drug Development Strategy Speaker: Zhang Kaiting, Associate Director, Pfizer	15:00-16:00 Panel Discussion: CGT process amplification and technology transfer Speaker: Hypo He, CMC, UNICET BIOTECH	Exhibition time/BioPartnering
16:00-17:00	16:00-17:00 Panel Discussion: Differentiated design and development ideas for popular targets Speaker: Johnson & Johnson, Associate Vice President of Clinical R&D Medicine	16:00-17:00 Panel Discussion: Experience Sharing on Quality Analysis of Cell Therapy Speaker: Qinjun Zhao, Director of Quality Unit, Beijing DCTY Biotech Yonghong Sun, QA Director, BRL Medicine Eric Xu, Sr. Director of manufacturing, Legend biotech	Exhibition time/BioPartnering



# BIOCHINA 2025 Brainstorming

Date	March 13th	March 14th	March 15th
	[Brainstorming] Biologic drug R&D/Process/Quality/Production.	[Brainstorming] Biologic drug R&D/Process/Quality/Production.	[Brainstorming] Biologic drug R&D/Process/Quality/Production.
09:00-10:00	Exhibition time/BioPartnering	09:00-10:00 Panel Discussion:ADC R&D Strategy Planner: Zhou Wei,Senior Director,Mabwell Speaker: Bliss Bio,Senior Director of Small Molecules	09:00-10:00Case: Continuous process validation for commercial production of antibody drugs Speaker: Lafite He, Head of Manufacturing, AKESO
10:00-11:00	Exhibition time/BioPartnering	10:00-11:00 Case: Design Ideas and Practice of Dual Anti ADC Speaker: Cai Huang, Vice President, Doer Biologics . ,	10:00-11:00Case: Thoughts on the Process of Factory Design and Construction Speaker: Wangwen Zhao, Manager,Shandong Boan biotech
12:00-13:00	12:00-13:00 Case: Technology Transfer and Process Validation Speaker: CHIA TAI TIANQING PHARMACEUTICAL,Head of Technology Department	12:00-13:00 Panel Discussion:Sharing of quality analysis related cases Speaker: Helen Liu,Senior Director,Zai lab Zai Lab Limited,Senior Director of Quality Control. China Resources Biopharma, Executive Director of Analytical Development and Quality Control.	12:00-13:00Panel Discussion:Factory design and engineering optimization Speaker: Linman Yang, Senior Director, Innovent Biologics(suzhou) Come.Ltd. Wan Yuxiang, Vice director, BioRay
13:00-14:00	13:00-14:00 Case: Aseptic assurance of monoclonal antibody based biological products Speaker: Yu Jiang,Director of Formulation, Suzhou Zhonghe Biomedical Technology .	13:00-14:00Panel Discussion:Discussion on Data Integrity and High Quality Production from the Design and Implementation of LIMS System Speaker: Junshipharma,Deputy Director of Quality Assurance	Exhibition time/BioPartnering
15:00-16:00	15:00-16:00 Case:Audit Items for Software as a Service (SaaS) Providers	15:00-16:00Case: Commercial production reduces costs and reases efficiency Speaker: Yilong Xie,Senior Department Manager,SHUNXIN PHARMACEUTICALS OF CHIATAI TIANQING	Exhibition time/BioPartnering
16:00-17:00	16:00-17:00 Panel Discussion: Formulation development Speaker: Ying Luo,Associate director,Lepu biopharma Zhen Yan ,Director of Final Product Development,Hengrui Pharmaceuticals	16;00-17:00 Case: Exploration of Cost Reduction and Efficiency Enhancement Strategies in Commercial Production of Biological Products Speaker: Lu Jiansheng,general manager,Nanjing Shunxin Pharmaceuticals	Exhibition time/BioPartnering

# BIOCHINA 2025 Exhibition and Attendee Activities

## Exhibition Overview

**BIOCHINA 2025 (10th Edition)** will feature five major exhibition halls, with a dedicated International Pavilion, covering raw materials and reagents, consumables, laboratory instruments, pharmaceutical equipment, and technology services. The total exhibition area will span 50,000 square meters, empowering collaboration across the upstream and downstream sectors of China's pharmaceutical industry and providing a platform for cooperation and exchange between domestic and international industry stakeholders.

**Reagent Raw Materials Hall** brings together a full range of raw materials and reagents used in every stage of pharmaceutical R&D, production, and quality control processes. This includes cell culture reagents, diagnostic reagents, and excipients for biologics, among others.

**Consumables Pavilion** brings together products used throughout the entire pharmaceutical process, including cell culture consumables, purification and filtration consumables and packaging materials, protective equipment, and other consumable products.

**Laboratory Instruments Hall** brings together a wide range of laboratory instruments and equipment for various applications, including analytical testing instruments, low-temperature storage equipment, and automation/intelligent instruments. The Pharmaceutical Equipment Pavilion gathers suppliers of various types of equipment used in the pharmaceutical industry, including bioreactors, liquid handling systems, chromatography and filtration systems, packaging equipment, and more.

**International Services Hall** brings together a variety of domestic and international CROs and CDMOs, as well as engineering services, logistics and cold chain solutions, software solutions, and park services as well as national pavilions from various overseas countries, as well as international pharmaceutical companies and a wide range of upstream suppliers and service providers.

## Pharmaceutical Equipment Experience Zone

### Exhibition Halls Spotlight

- New Equipment Hands-On Experience
- Independent Module Operation Demo
- Simulated Factory Tour

### Audience Participation

- Guided Group Customized
- Customized Tours & Explanations for Specific job function
- Individual Tour (By Appointment)

## Exhibition Scoring Activities – Research Institution

## Distributor Networking Event



# BIO CHINA

International Convention

# 2025

March 13-15, 2025  
Suzhou International Expo Center



▶▶ BIOCHINA ◀◀

Connecting Innovators, Enabling Bio-industry.  
China's leading communication platform in Bio-industry



▶▶ BioBD Group ◀◀



▶▶ BIOCHINA GCD Group ◀◀  
(Global Clinical Group)

✉ [BIOCHINA@enmore.com](mailto:BIOCHINA@enmore.com)

